JP2012504639A - ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 - Google Patents
ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 Download PDFInfo
- Publication number
- JP2012504639A JP2012504639A JP2011530218A JP2011530218A JP2012504639A JP 2012504639 A JP2012504639 A JP 2012504639A JP 2011530218 A JP2011530218 A JP 2011530218A JP 2011530218 A JP2011530218 A JP 2011530218A JP 2012504639 A JP2012504639 A JP 2012504639A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- independently selected
- alkynyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims abstract description 100
- 206010013774 Dry eye Diseases 0.000 title claims description 68
- 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 36
- 201000010099 disease Diseases 0.000 title description 25
- 238000000034 method Methods 0.000 claims abstract description 94
- 239000000203 mixture Substances 0.000 claims abstract description 88
- 125000000217 alkyl group Chemical group 0.000 claims description 558
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 286
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 251
- 125000003118 aryl group Chemical group 0.000 claims description 248
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 248
- 125000001072 heteroaryl group Chemical group 0.000 claims description 237
- 125000005843 halogen group Chemical group 0.000 claims description 231
- 125000001424 substituent group Chemical group 0.000 claims description 211
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 175
- 125000003342 alkenyl group Chemical group 0.000 claims description 160
- 125000000304 alkynyl group Chemical group 0.000 claims description 158
- 125000005311 halosulfanyl group Chemical group 0.000 claims description 156
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 147
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 134
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 132
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 132
- 239000003814 drug Substances 0.000 claims description 122
- 229910052799 carbon Inorganic materials 0.000 claims description 119
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 118
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 107
- 229910052739 hydrogen Inorganic materials 0.000 claims description 105
- 229940079593 drug Drugs 0.000 claims description 96
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 90
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 90
- -1 ally Chemical group 0.000 claims description 89
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 84
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 82
- 229920000642 polymer Polymers 0.000 claims description 65
- 229910052717 sulfur Inorganic materials 0.000 claims description 63
- 125000000732 arylene group Chemical group 0.000 claims description 50
- 125000002947 alkylene group Chemical group 0.000 claims description 47
- 239000003795 chemical substances by application Substances 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 44
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 44
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 42
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 42
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 40
- 125000005549 heteroarylene group Chemical group 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 30
- 125000004450 alkenylene group Chemical group 0.000 claims description 29
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 29
- 125000003545 alkoxy group Chemical group 0.000 claims description 28
- 125000004419 alkynylene group Chemical group 0.000 claims description 27
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 21
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 21
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 208000024891 symptom Diseases 0.000 claims description 12
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 11
- 230000001629 suppression Effects 0.000 claims description 11
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- 238000002054 transplantation Methods 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 229920001610 polycaprolactone Polymers 0.000 claims description 9
- 239000004632 polycaprolactone Substances 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 8
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 8
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 8
- 230000004393 visual impairment Effects 0.000 claims description 8
- 125000005466 alkylenyl group Chemical group 0.000 claims description 7
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 7
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 239000004005 microsphere Substances 0.000 claims description 7
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 6
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 210000000744 eyelid Anatomy 0.000 claims description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 6
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 108010036949 Cyclosporine Proteins 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 5
- 229960001265 ciclosporin Drugs 0.000 claims description 5
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920002635 polyurethane Polymers 0.000 claims description 5
- 239000004814 polyurethane Substances 0.000 claims description 5
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 206010047571 Visual impairment Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims description 4
- 210000003786 sclera Anatomy 0.000 claims description 4
- 208000029257 vision disease Diseases 0.000 claims description 4
- JSFATNQSLKRBCI-VAEKSGALSA-N 15(S)-HETE Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-VAEKSGALSA-N 0.000 claims description 3
- 201000004569 Blindness Diseases 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 208000002691 Choroiditis Diseases 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 claims description 3
- 208000003971 Posterior uveitis Diseases 0.000 claims description 3
- 206010038910 Retinitis Diseases 0.000 claims description 3
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims description 3
- 206010039705 Scleritis Diseases 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 229950003529 diquafosol Drugs 0.000 claims description 3
- 229960003722 doxycycline Drugs 0.000 claims description 3
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 201000004614 iritis Diseases 0.000 claims description 3
- 229960004023 minocycline Drugs 0.000 claims description 3
- 229960001416 pilocarpine Drugs 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
- HFNKQEVNSGCOJV-UHFFFAOYSA-N 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1CCCC1 HFNKQEVNSGCOJV-UHFFFAOYSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- 102100034719 Extracellular glycoprotein lacritin Human genes 0.000 claims description 2
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 claims description 2
- 229920001386 Gefarnate Polymers 0.000 claims description 2
- 101001090521 Homo sapiens Extracellular glycoprotein lacritin Proteins 0.000 claims description 2
- 206010020852 Hypertonia Diseases 0.000 claims description 2
- 239000004100 Oxytetracycline Substances 0.000 claims description 2
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229950003246 ecabet Drugs 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 229940043075 fluocinolone Drugs 0.000 claims description 2
- 229960003779 gefarnate Drugs 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 229960000625 oxytetracycline Drugs 0.000 claims description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 2
- 235000019366 oxytetracycline Nutrition 0.000 claims description 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 2
- 229960005330 pimecrolimus Drugs 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 229950004535 rebamipide Drugs 0.000 claims description 2
- 229960001487 rimexolone Drugs 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 2
- 229960003604 testosterone Drugs 0.000 claims description 2
- 229960003433 thalidomide Drugs 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 14
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 7
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000001041 indolyl group Chemical group 0.000 claims 6
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 5
- MQSBVYINPUYVMT-UHFFFAOYSA-N 1-tert-butyl-3-methylpyrazole Chemical compound CC=1C=CN(C(C)(C)C)N=1 MQSBVYINPUYVMT-UHFFFAOYSA-N 0.000 claims 4
- OQDXAOLZTHIGKG-UHFFFAOYSA-N 5-methyl-3-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OQDXAOLZTHIGKG-UHFFFAOYSA-N 0.000 claims 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims 2
- 210000003488 posterior eye segment Anatomy 0.000 claims 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- SGCCZRJOSHPMOH-UHFFFAOYSA-N 3-(cyanomethyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]cyclobutane-1-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C1(CC#N)CC(C#N)C1 SGCCZRJOSHPMOH-UHFFFAOYSA-N 0.000 claims 1
- JDHDSHAJOIQVCP-UHFFFAOYSA-N 5-cyclopropyl-3-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1,2,4-oxadiazole Chemical compound C1CC1C1=NC(C=2C=3C=CNC=3N=CC=2)=NO1 JDHDSHAJOIQVCP-UHFFFAOYSA-N 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 239000013011 aqueous formulation Substances 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 1
- 229960003744 loteprednol etabonate Drugs 0.000 claims 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 1
- DOZYTHNHLLSNIK-JOKMOOFLSA-M mycophenolate sodium Chemical compound [Na+].OC1=C(C\C=C(/C)CCC([O-])=O)C(OC)=C(C)C2=C1C(=O)OC2 DOZYTHNHLLSNIK-JOKMOOFLSA-M 0.000 claims 1
- 229960000951 mycophenolic acid Drugs 0.000 claims 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims 1
- RCVIHORGZULVTN-YGJXXQMASA-M sodium;(1r,4as,10ar)-1,4a-dimethyl-7-propan-2-yl-6-sulfo-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate Chemical compound [Na+].OC(=O)[C@@](C)([C@@H]1CC2)CCC[C@]1(C)C1=C2C=C(C(C)C)C(S([O-])(=O)=O)=C1 RCVIHORGZULVTN-YGJXXQMASA-M 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 abstract description 3
- 239000010408 film Substances 0.000 description 43
- 210000001508 eye Anatomy 0.000 description 28
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 102000015617 Janus Kinases Human genes 0.000 description 21
- 108010024121 Janus Kinases Proteins 0.000 description 21
- 239000011159 matrix material Substances 0.000 description 20
- 239000002245 particle Substances 0.000 description 20
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 19
- 108010019421 Janus Kinase 3 Proteins 0.000 description 18
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 14
- 210000004087 cornea Anatomy 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 14
- 239000000178 monomer Substances 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 12
- 238000012377 drug delivery Methods 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229920002125 Sokalan® Polymers 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000000375 suspending agent Substances 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000004561 lacrimal apparatus Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000003204 osmotic effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000004584 polyacrylic acid Substances 0.000 description 7
- 239000008247 solid mixture Substances 0.000 description 7
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229920002988 biodegradable polymer Polymers 0.000 description 6
- 239000004621 biodegradable polymer Substances 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 102000042838 JAK family Human genes 0.000 description 5
- 108091082332 JAK family Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 125000001475 halogen functional group Chemical group 0.000 description 5
- 239000003456 ion exchange resin Substances 0.000 description 5
- 229920003303 ion-exchange polymer Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 230000000414 obstructive effect Effects 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- TVGMVLZIRSLGAH-UHFFFAOYSA-N 3-(3-methylsulfonylphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CS(=O)(=O)C1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 TVGMVLZIRSLGAH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 229920002148 Gellan gum Polymers 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000607 artificial tear Substances 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000005499 meniscus Effects 0.000 description 3
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229920000570 polyether Polymers 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 229960004605 timolol Drugs 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- GDTGNZSOHXXADB-UHFFFAOYSA-N 1-phenyl-2-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propan-1-ol Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(C)C(O)C1=CC=CC=C1 GDTGNZSOHXXADB-UHFFFAOYSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- UCSUSZMJIDLGAR-UHFFFAOYSA-N 3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]-n,n-dimethylbenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 UCSUSZMJIDLGAR-UHFFFAOYSA-N 0.000 description 2
- XFFGCHGLVRFXST-UHFFFAOYSA-N 3-[3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]benzonitrile Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CC=CC(C#N)=C1 XFFGCHGLVRFXST-UHFFFAOYSA-N 0.000 description 2
- MDMRCXQIINSRGZ-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-3-[5-(trifluoromethyl)pyridin-3-yl]propanenitrile Chemical compound FC(F)(F)C1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 MDMRCXQIINSRGZ-UHFFFAOYSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000009043 Chemical Burns Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 241000134970 Cornales Species 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 2
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004175 meibomian gland Anatomy 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229940023490 ophthalmic product Drugs 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940061341 retisert Drugs 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229960001922 sodium perborate Drugs 0.000 description 2
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- SFWLDKQAUHFCBS-AOEYGKNYSA-N (1S,4S,13S,16S,19S,22S,25S,28R,31S,37S,40S,41S,44R,47S,50S,53S,56R,65S,70S)-44-amino-47-(4-aminobutyl)-4,16,22-tribenzyl-31-[(R)-carboxy(hydroxy)methyl]-2,5,14,17,20,23,26,29,32,35,38,45,48,51,54,57,67-heptadecahydroxy-37-(2-hydroxy-2-iminoethyl)-50-(3-hydroxy-3-iminopropyl)-41,70-dimethyl-8-oxo-25-propan-2-yl-42,69,72-trithia-3,6,9,15,18,21,24,27,30,33,36,39,46,49,52,55,58,60,66-nonadecazapentacyclo[38.18.9.319,56.328,53.09,13]triheptaconta-2,5,14,17,20,23,26,29,32,35,38,45,48,51,54,57,66-heptadecaene-65-carboxylic acid Chemical compound CC(C)[C@@H]1\N=C(O)/[C@H](Cc2ccccc2)\N=C(O)/[C@@H]2\N=C(O)/[C@H](Cc3ccccc3)\N=C(O)/[C@@H]3CCCN3C(=O)C\N=C(O)/[C@H](Cc3ccccc3)\N=C(O)/[C@@H]3CNCCCC[C@H](\N=C(O)\[C@@H]4\N=C(O)\[C@H](CC(O)=N)\N=C(O)\C\N=C(O)/[C@@H](\N=C(O)\[C@H](CSC[C@@H](N=C(O)[C@H](CCC(O)=N)N=C(O)[C@H](CCCCN)N=C(O)[C@@H](N)CS[C@H]4C)C(O)=N[C@@H](CS[C@H]2C)C(O)=N3)\N=C1\O)[C@@H](O)C(O)=O)C(O)=O SFWLDKQAUHFCBS-AOEYGKNYSA-N 0.000 description 1
- CIDUJQMULVCIBT-CWCLBWQUSA-N (2R,3R,4R,5R)-2-[(1S,2S,3S,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound CCN[C@@H]1C[C@H](N)[C@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O CIDUJQMULVCIBT-CWCLBWQUSA-N 0.000 description 1
- BSUKKOMNQGNSGP-QPJJXVBHSA-N (2e)-2-ethylidenehexanoic acid Chemical compound CCCC\C(=C/C)C(O)=O BSUKKOMNQGNSGP-QPJJXVBHSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- PHOZOHFUXHPOCK-QMMMGPOBSA-N (2s)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound N1C(=O)[C@H](CC)SC11CCN(C)CC1 PHOZOHFUXHPOCK-QMMMGPOBSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical group O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- MCKJPJYRCPANCC-XLXYOEISSA-N (8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 MCKJPJYRCPANCC-XLXYOEISSA-N 0.000 description 1
- KHQDAOSIOHTJCX-OWOJBTEDSA-N (E)-3-(4,4-dihydroxycyclohexa-1,5-dien-1-yl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CCC(O)(O)C=C1 KHQDAOSIOHTJCX-OWOJBTEDSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IAKAIJRXUQFDRQ-ZPYUXNTASA-N (e)-but-2-enoic acid;2-methylprop-2-enoic acid Chemical compound C\C=C\C(O)=O.CC(=C)C(O)=O IAKAIJRXUQFDRQ-ZPYUXNTASA-N 0.000 description 1
- AQPOVPIJVUBVKE-IFRROFPPSA-N (e)-n-methoxy-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentan-1-imine Chemical compound C1=NN(C(C\C=N\OC)CC)C=C1C1=NC=NC2=C1C=CN2 AQPOVPIJVUBVKE-IFRROFPPSA-N 0.000 description 1
- IDZKTNAVHPJBJP-KPSZGOFPSA-N (ne)-n-[3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentylidene]hydroxylamine Chemical compound C1=NN(C(C\C=N\O)CC)C=C1C1=NC=NC2=C1C=CN2 IDZKTNAVHPJBJP-KPSZGOFPSA-N 0.000 description 1
- AQPOVPIJVUBVKE-SCDVKCJHSA-N (z)-n-methoxy-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentan-1-imine Chemical compound C1=NN(C(C\C=N/OC)CC)C=C1C1=NC=NC2=C1C=CN2 AQPOVPIJVUBVKE-SCDVKCJHSA-N 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- CQEWNJHBMWSTTD-UHFFFAOYSA-N 1-(1h-pyrrolo[2,3-b]pyridin-4-yl)indazole Chemical compound N1=CC2=CC=CC=C2N1C1=C2C=CNC2=NC=C1 CQEWNJHBMWSTTD-UHFFFAOYSA-N 0.000 description 1
- CJVMUHAGCRAOIH-UHFFFAOYSA-N 1-[3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]phenyl]-3-propan-2-ylurea Chemical compound CC(C)NC(=O)NC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 CJVMUHAGCRAOIH-UHFFFAOYSA-N 0.000 description 1
- XTPGFCMNNRGNLX-UHFFFAOYSA-N 1-[[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]methyl]cyclopropane-1-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC1(C#N)CC1 XTPGFCMNNRGNLX-UHFFFAOYSA-N 0.000 description 1
- YGNBHNQFLAJKMK-UHFFFAOYSA-N 1-benzyl-4-[[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]methyl]pyrrolidin-2-one Chemical compound O=C1CC(CN2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)CN1CC1=CC=CC=C1 YGNBHNQFLAJKMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HKTMUSRKGJOFQT-UHFFFAOYSA-N 1-phenyl-2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]ethanone Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC(=O)C1=CC=CC=C1 HKTMUSRKGJOFQT-UHFFFAOYSA-N 0.000 description 1
- INGUHLZZQKDACC-UHFFFAOYSA-N 1-phenyl-2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propan-1-one Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C(=O)C1=CC=CC=C1 INGUHLZZQKDACC-UHFFFAOYSA-N 0.000 description 1
- NTYBSPKWKAEMKG-UHFFFAOYSA-N 1-phenyl-2-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propan-1-one Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(C)C(=O)C1=CC=CC=C1 NTYBSPKWKAEMKG-UHFFFAOYSA-N 0.000 description 1
- BUWXSBMIJDXLCV-UHFFFAOYSA-N 2,2-dimethyl-6-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]hexanenitrile Chemical compound C1=NN(CCCCC(C)(C)C#N)C=C1C1=CC=NC2=C1C=CN2 BUWXSBMIJDXLCV-UHFFFAOYSA-N 0.000 description 1
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- DSAYAFZWRDYBQY-UHFFFAOYSA-N 2,5-dimethylhexa-1,5-diene Chemical compound CC(=C)CCC(C)=C DSAYAFZWRDYBQY-UHFFFAOYSA-N 0.000 description 1
- HFJZXAJUYMCRIQ-UHFFFAOYSA-N 2-(1h-pyrrolo[2,3-b]pyridin-4-yl)indazole Chemical compound C1=C2C=CC=CC2=NN1C1=C2C=CNC2=NC=C1 HFJZXAJUYMCRIQ-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- UIERETOOQGIECD-ARJAWSKDSA-M 2-Methyl-2-butenoic acid Natural products C\C=C(\C)C([O-])=O UIERETOOQGIECD-ARJAWSKDSA-M 0.000 description 1
- LPZOXPNOAVPYMP-UHFFFAOYSA-N 2-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]-1,3-benzoxazole Chemical compound C1=CC=C2OC(C3=CN(N=C3)C3=C4C=CNC4=NC=C3)=NC2=C1 LPZOXPNOAVPYMP-UHFFFAOYSA-N 0.000 description 1
- ZSJBIPMRABDQEV-UHFFFAOYSA-N 2-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]benzonitrile Chemical compound N#CC1=CC=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1 ZSJBIPMRABDQEV-UHFFFAOYSA-N 0.000 description 1
- BOLDWUBNHGCOKD-UHFFFAOYSA-N 2-[1-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]cyclopentyl]acetonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C1(CC#N)CCCC1 BOLDWUBNHGCOKD-UHFFFAOYSA-N 0.000 description 1
- IDFICYBUDIOWHA-UHFFFAOYSA-N 2-[1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]cyclohexyl]acetonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C1(CC#N)CCCCC1 IDFICYBUDIOWHA-UHFFFAOYSA-N 0.000 description 1
- WLWKNCAZCPIQKN-UHFFFAOYSA-N 2-[1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]cyclopentyl]acetonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C1(CC#N)CCCC1 WLWKNCAZCPIQKN-UHFFFAOYSA-N 0.000 description 1
- DZOWVAFBINXFOB-UHFFFAOYSA-N 2-[1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]cyclopropyl]acetonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C1(CC#N)CC1 DZOWVAFBINXFOB-UHFFFAOYSA-N 0.000 description 1
- XIJMVYDFXBOXJI-UHFFFAOYSA-N 2-[2-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]phenyl]acetonitrile Chemical compound N#CCC1=CC=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1 XIJMVYDFXBOXJI-UHFFFAOYSA-N 0.000 description 1
- XMDCTOCUQQUDPE-UHFFFAOYSA-N 2-[2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-5-(trifluoromethyl)phenyl]acetonitrile Chemical compound N#CCC1=CC(C(F)(F)F)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 XMDCTOCUQQUDPE-UHFFFAOYSA-N 0.000 description 1
- PAWUPHYEOOFEER-UHFFFAOYSA-N 2-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]pyridine-4-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CC(C#N)=CC=N1 PAWUPHYEOOFEER-UHFFFAOYSA-N 0.000 description 1
- OZLJQOZPOCBTPF-UHFFFAOYSA-N 2-[3-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-3-yl]phenoxy]acetonitrile Chemical compound N#CCOC1=CC=CC(C2=NN(C=C2)C=2C=3C=CNC=3N=CC=2)=C1 OZLJQOZPOCBTPF-UHFFFAOYSA-N 0.000 description 1
- RYIPUPLPSUMALJ-UHFFFAOYSA-N 2-[3-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]phenyl]acetonitrile Chemical compound N#CCC1=CC=CC(C2=CN(N=C2)C=2C=3C=CNC=3N=CC=2)=C1 RYIPUPLPSUMALJ-UHFFFAOYSA-N 0.000 description 1
- BIPPXMZRIQZSKE-UHFFFAOYSA-N 2-[3-chloro-2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-5-(trifluoromethyl)phenyl]acetonitrile Chemical compound N#CCC1=CC(C(F)(F)F)=CC(Cl)=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 BIPPXMZRIQZSKE-UHFFFAOYSA-N 0.000 description 1
- VYIIVQPPRDOYNI-UHFFFAOYSA-N 2-[3-methyl-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]phenyl]acetonitrile Chemical compound CC1=CC(CC#N)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 VYIIVQPPRDOYNI-UHFFFAOYSA-N 0.000 description 1
- KHVBCXARHGPTLW-UHFFFAOYSA-N 2-[3-methyl-4-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]phenyl]acetonitrile Chemical compound CC1=CC(CC#N)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 KHVBCXARHGPTLW-UHFFFAOYSA-N 0.000 description 1
- PSWCXILVFVGISQ-UHFFFAOYSA-N 2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-3-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC(C#N)=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 PSWCXILVFVGISQ-UHFFFAOYSA-N 0.000 description 1
- YKKSCJLAOCFSQC-UHFFFAOYSA-N 2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-5-(trifluoromethyl)benzonitrile Chemical compound N#CC1=CC(C(F)(F)F)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 YKKSCJLAOCFSQC-UHFFFAOYSA-N 0.000 description 1
- UXKVRHSAYBHZJH-UHFFFAOYSA-N 2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound N#CC1=CC=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 UXKVRHSAYBHZJH-UHFFFAOYSA-N 0.000 description 1
- JYLQHLUANOQCSK-UHFFFAOYSA-N 2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]cyclohexan-1-ol Chemical compound OC1CCCCC1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 JYLQHLUANOQCSK-UHFFFAOYSA-N 0.000 description 1
- QAUAPRNFAWLMAD-UHFFFAOYSA-N 2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]cyclohexane-1-carbonitrile Chemical compound N#CC1CCCCC1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 QAUAPRNFAWLMAD-UHFFFAOYSA-N 0.000 description 1
- QRYMJFRINFRLTH-UHFFFAOYSA-N 2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=NN(C(C#N)C)C=C1C1=CC=NC2=C1C=CN2 QRYMJFRINFRLTH-UHFFFAOYSA-N 0.000 description 1
- IZANPVOIMADAJP-UHFFFAOYSA-N 2-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-n-[3-(trifluoromethyl)phenyl]propanamide Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(C)C(=O)NC1=CC=CC(C(F)(F)F)=C1 IZANPVOIMADAJP-UHFFFAOYSA-N 0.000 description 1
- PHJOKSBOVSNTQC-UHFFFAOYSA-N 2-[4-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]phenoxy]acetonitrile Chemical compound C1=CC(OCC#N)=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1 PHJOKSBOVSNTQC-UHFFFAOYSA-N 0.000 description 1
- VEQUBLQCMVKKLZ-UHFFFAOYSA-N 2-[4-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]phenyl]acetonitrile Chemical compound C1=CC(CC#N)=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1 VEQUBLQCMVKKLZ-UHFFFAOYSA-N 0.000 description 1
- GMENCIXDAWPZEP-UHFFFAOYSA-N 2-[4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]phenyl]acetonitrile Chemical compound C1=CC(CC#N)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 GMENCIXDAWPZEP-UHFFFAOYSA-N 0.000 description 1
- BORJGIRWWXWVED-UHFFFAOYSA-N 2-[4-[[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]methyl]phenyl]benzonitrile Chemical compound N#CC1=CC=CC=C1C(C=C1)=CC=C1CN1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 BORJGIRWWXWVED-UHFFFAOYSA-N 0.000 description 1
- NENHXFFOWUQWPW-UHFFFAOYSA-N 2-[4-bromo-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-3-yl]isoindole-1,3-dione Chemical compound N1=C(N2C(C3=CC=CC=C3C2=O)=O)C(Br)=CN1C1=CC=NC2=C1C=CN2 NENHXFFOWUQWPW-UHFFFAOYSA-N 0.000 description 1
- ARUKQQDZRIXOQR-UHFFFAOYSA-N 2-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]pentanenitrile Chemical compound S1C(C(C#N)CCC)=NC=C1C1=NC=NC2=C1C=CN2 ARUKQQDZRIXOQR-UHFFFAOYSA-N 0.000 description 1
- VQUZGUQADNFJDS-UHFFFAOYSA-N 2-[5-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-2-(trifluoromethyl)phenyl]acetonitrile Chemical compound C1=C(CC#N)C(C(F)(F)F)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 VQUZGUQADNFJDS-UHFFFAOYSA-N 0.000 description 1
- VLJQJXSQIHYYFI-UHFFFAOYSA-N 2-[[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]methyl]benzonitrile Chemical compound N#CC1=CC=CC=C1CN1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 VLJQJXSQIHYYFI-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- RYNDYESLUKWOEE-UHFFFAOYSA-N 2-benzylprop-2-enoic acid Chemical compound OC(=O)C(=C)CC1=CC=CC=C1 RYNDYESLUKWOEE-UHFFFAOYSA-N 0.000 description 1
- CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 1
- GQWKHZGBVWSNHU-UHFFFAOYSA-N 2-chloro-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound ClC1=C(C#N)C=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 GQWKHZGBVWSNHU-UHFFFAOYSA-N 0.000 description 1
- FQHUWSPRTMWLFA-UHFFFAOYSA-N 2-cyclohexylprop-2-enoic acid Chemical compound OC(=O)C(=C)C1CCCCC1 FQHUWSPRTMWLFA-UHFFFAOYSA-N 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- MYDROCLKHWOEDX-UHFFFAOYSA-N 2-fluoro-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound C1=C(C#N)C(F)=CC(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 MYDROCLKHWOEDX-UHFFFAOYSA-N 0.000 description 1
- YBPMWNGAEBCCDB-UHFFFAOYSA-N 2-methyl-2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propanamide Chemical compound C1=NN(C(C)(C(N)=O)C)C=C1C1=CC=NC2=C1C=CN2 YBPMWNGAEBCCDB-UHFFFAOYSA-N 0.000 description 1
- HBHJBFMTFMZIKX-UHFFFAOYSA-N 2-methyl-2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propanoic acid Chemical compound C1=NN(C(C)(C(O)=O)C)C=C1C1=CC=NC2=C1C=CN2 HBHJBFMTFMZIKX-UHFFFAOYSA-N 0.000 description 1
- AIKDVCDEFQNVEY-UHFFFAOYSA-N 2-methyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=NN(CC(C)C#N)C=C1C1=NC=NC2=C1C=CN2 AIKDVCDEFQNVEY-UHFFFAOYSA-N 0.000 description 1
- CXIOLADOABWRBC-UHFFFAOYSA-N 2-phenyl-4-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1,3-thiazole Chemical compound C1=CN=C2NC=CC2=C1C(N=1)=CSC=1C1=CC=CC=C1 CXIOLADOABWRBC-UHFFFAOYSA-N 0.000 description 1
- JRZBMROMBFSQJX-UHFFFAOYSA-N 2-phenyl-5-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1,3-thiazole Chemical compound C1=CN=C2NC=CC2=C1C(S1)=CN=C1C1=CC=CC=C1 JRZBMROMBFSQJX-UHFFFAOYSA-N 0.000 description 1
- ONPJWQSDZCGSQM-UHFFFAOYSA-N 2-phenylprop-2-enoic acid Chemical compound OC(=O)C(=C)C1=CC=CC=C1 ONPJWQSDZCGSQM-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- JGCHNVFNEAQVEF-UHFFFAOYSA-N 3,3-dimethyl-1-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]butan-2-one Chemical compound C1=NN(CC(=O)C(C)(C)C)C=C1C1=CC=NC2=C1C=CN2 JGCHNVFNEAQVEF-UHFFFAOYSA-N 0.000 description 1
- ZVRQJPRMMAJUMZ-UHFFFAOYSA-N 3-(1-benzofuran-2-yl)-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C=1C2=CC=CC=C2OC=1C(CC#N)N(N=C1)C=C1C1=CC=NC2=C1C=CN2 ZVRQJPRMMAJUMZ-UHFFFAOYSA-N 0.000 description 1
- TXRBKHPRGSORKD-UHFFFAOYSA-N 3-(1-methylpyrazol-4-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=NN(C)C=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 TXRBKHPRGSORKD-UHFFFAOYSA-N 0.000 description 1
- QIOPTSMJYWGZQX-UHFFFAOYSA-N 3-(2-bromo-1,3-thiazol-5-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound S1C(Br)=NC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 QIOPTSMJYWGZQX-UHFFFAOYSA-N 0.000 description 1
- BFFDLHXFOKTJJO-UHFFFAOYSA-N 3-(2-bromopyridin-4-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=NC(Br)=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 BFFDLHXFOKTJJO-UHFFFAOYSA-N 0.000 description 1
- VJOPGWDAQQVHHK-UHFFFAOYSA-N 3-(2-methoxypyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound COC1=NC=CC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 VJOPGWDAQQVHHK-UHFFFAOYSA-N 0.000 description 1
- KTQQQXLFJWUKOM-UHFFFAOYSA-N 3-(3,5-dibromophenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound BrC1=CC(Br)=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 KTQQQXLFJWUKOM-UHFFFAOYSA-N 0.000 description 1
- MBADRWYPVDLHQC-UHFFFAOYSA-N 3-(3,5-dimethyl-1,2-oxazol-4-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CC1=NOC(C)=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 MBADRWYPVDLHQC-UHFFFAOYSA-N 0.000 description 1
- ZKWJALOZNSEXDT-UHFFFAOYSA-N 3-(3-aminophenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound NC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 ZKWJALOZNSEXDT-UHFFFAOYSA-N 0.000 description 1
- FWUMPVDWWFNKEW-UHFFFAOYSA-N 3-(3-bromophenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound BrC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 FWUMPVDWWFNKEW-UHFFFAOYSA-N 0.000 description 1
- YBVTVMVSICZEJE-UHFFFAOYSA-N 3-(3-chlorophenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound ClC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 YBVTVMVSICZEJE-UHFFFAOYSA-N 0.000 description 1
- WCEMDJMNQNQPFW-UHFFFAOYSA-N 3-(3-ethylsulfanylphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CCSC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 WCEMDJMNQNQPFW-UHFFFAOYSA-N 0.000 description 1
- ZVSGNVMLGDTCMY-UHFFFAOYSA-N 3-(3-ethylsulfinylphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CCS(=O)C1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 ZVSGNVMLGDTCMY-UHFFFAOYSA-N 0.000 description 1
- NDFZUCJGYPZUBI-UHFFFAOYSA-N 3-(3-ethylsulfonylphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CCS(=O)(=O)C1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 NDFZUCJGYPZUBI-UHFFFAOYSA-N 0.000 description 1
- RTSDRORMCIEHBS-UHFFFAOYSA-N 3-(3-methoxyphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound COC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 RTSDRORMCIEHBS-UHFFFAOYSA-N 0.000 description 1
- OKARDSIHOMFMDX-UHFFFAOYSA-N 3-(3-methylimidazol-4-yl)-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CN1C=NC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 OKARDSIHOMFMDX-UHFFFAOYSA-N 0.000 description 1
- CETUSXLETHLLDA-UHFFFAOYSA-N 3-(3-nitrophenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound [O-][N+](=O)C1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 CETUSXLETHLLDA-UHFFFAOYSA-N 0.000 description 1
- IOUXTQRLYQBBGB-UHFFFAOYSA-N 3-(3-phenoxyphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 IOUXTQRLYQBBGB-UHFFFAOYSA-N 0.000 description 1
- MNQTZPUKIKBGQQ-UHFFFAOYSA-N 3-(3-pyridin-3-ylphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CC=CC=1C1=CC=CN=C1 MNQTZPUKIKBGQQ-UHFFFAOYSA-N 0.000 description 1
- OSCQVFWTKPUFPB-UHFFFAOYSA-N 3-(3-pyridin-4-ylphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CC=CC=1C1=CC=NC=C1 OSCQVFWTKPUFPB-UHFFFAOYSA-N 0.000 description 1
- ZZVBYTXBDQSDEO-UHFFFAOYSA-N 3-(4-bromofuran-2-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound BrC1=COC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 ZZVBYTXBDQSDEO-UHFFFAOYSA-N 0.000 description 1
- TUWDLPZKZZWETP-UHFFFAOYSA-N 3-(4-bromopyridin-2-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound BrC1=CC=NC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 TUWDLPZKZZWETP-UHFFFAOYSA-N 0.000 description 1
- UCCNYUVJUXIHNU-UHFFFAOYSA-N 3-(4-bromothiophen-2-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound BrC1=CSC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 UCCNYUVJUXIHNU-UHFFFAOYSA-N 0.000 description 1
- KPRKIQRSNRKDLZ-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=CC(OC)=CC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 KPRKIQRSNRKDLZ-UHFFFAOYSA-N 0.000 description 1
- QQFUXXKQJAYBQS-UHFFFAOYSA-N 3-(4-methylsulfanylphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=CC(SC)=CC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 QQFUXXKQJAYBQS-UHFFFAOYSA-N 0.000 description 1
- LDVFGVGSGXCINC-UHFFFAOYSA-N 3-(4-methylsulfinylphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=CC(S(=O)C)=CC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 LDVFGVGSGXCINC-UHFFFAOYSA-N 0.000 description 1
- ILRDJUQACMZKCE-UHFFFAOYSA-N 3-(4-methylsulfonylphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 ILRDJUQACMZKCE-UHFFFAOYSA-N 0.000 description 1
- ZJLCHGSAJYTECE-UHFFFAOYSA-N 3-(5-bromo-2-fluorophenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound FC1=CC=C(Br)C=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 ZJLCHGSAJYTECE-UHFFFAOYSA-N 0.000 description 1
- INARHFWDLBEPIB-UHFFFAOYSA-N 3-(5-bromo-2-methoxyphenyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound COC1=CC=C(Br)C=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 INARHFWDLBEPIB-UHFFFAOYSA-N 0.000 description 1
- OWZQRLUHNBYDBD-UHFFFAOYSA-N 3-(5-bromopyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound BrC1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 OWZQRLUHNBYDBD-UHFFFAOYSA-N 0.000 description 1
- JZSVBEWOXUMHTF-UHFFFAOYSA-N 3-(5-bromopyridin-3-yl)-3-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]propanenitrile Chemical compound BrC1=CN=CC(C(CC#N)C=2SC(=CN=2)C=2C=3C=CNC=3N=CN=2)=C1 JZSVBEWOXUMHTF-UHFFFAOYSA-N 0.000 description 1
- QIUUNPJERHCTRI-UHFFFAOYSA-N 3-(5-cyclohexylsulfanylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CN=CC=1SC1CCCCC1 QIUUNPJERHCTRI-UHFFFAOYSA-N 0.000 description 1
- GWFVWTNKERDISB-UHFFFAOYSA-N 3-(5-cyclohexylsulfinylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C=1N=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1S(=O)C1CCCCC1 GWFVWTNKERDISB-UHFFFAOYSA-N 0.000 description 1
- YOOBQEXFWQQOPL-UHFFFAOYSA-N 3-(5-cyclohexylsulfonylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C=1N=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1S(=O)(=O)C1CCCCC1 YOOBQEXFWQQOPL-UHFFFAOYSA-N 0.000 description 1
- LWJWGUUTNLAKQG-UHFFFAOYSA-N 3-(5-ethylsulfanylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CCSC1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 LWJWGUUTNLAKQG-UHFFFAOYSA-N 0.000 description 1
- JXLJWUBYEHEJRB-UHFFFAOYSA-N 3-(5-ethylsulfinylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CCS(=O)C1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 JXLJWUBYEHEJRB-UHFFFAOYSA-N 0.000 description 1
- UIQXHRAQESDSNP-UHFFFAOYSA-N 3-(5-ethylsulfonylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CCS(=O)(=O)C1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 UIQXHRAQESDSNP-UHFFFAOYSA-N 0.000 description 1
- HAMDNSCESBAUIU-UHFFFAOYSA-N 3-(5-ethynylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C#CC1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 HAMDNSCESBAUIU-UHFFFAOYSA-N 0.000 description 1
- ABPKTQVYTSFZQN-UHFFFAOYSA-N 3-(5-formylthiophen-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound S1C(C=O)=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 ABPKTQVYTSFZQN-UHFFFAOYSA-N 0.000 description 1
- ARTUSOXONCFJSQ-UHFFFAOYSA-N 3-(5-methoxypyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound COC1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 ARTUSOXONCFJSQ-UHFFFAOYSA-N 0.000 description 1
- TZNUFUUVSLCYTD-UHFFFAOYSA-N 3-(5-morpholin-4-ylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CN=CC=1N1CCOCC1 TZNUFUUVSLCYTD-UHFFFAOYSA-N 0.000 description 1
- CWPDWRNLICNHPU-UHFFFAOYSA-N 3-(5-phenylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CN=CC=1C1=CC=CC=C1 CWPDWRNLICNHPU-UHFFFAOYSA-N 0.000 description 1
- GGYPBLHKXGXDIP-UHFFFAOYSA-N 3-(5-phenylsulfanylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CN=CC=1SC1=CC=CC=C1 GGYPBLHKXGXDIP-UHFFFAOYSA-N 0.000 description 1
- KTXHYLGUVWAFRU-UHFFFAOYSA-N 3-(5-propan-2-ylsulfanylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CC(C)SC1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 KTXHYLGUVWAFRU-UHFFFAOYSA-N 0.000 description 1
- XEVUCQWBQWHHBF-UHFFFAOYSA-N 3-(5-propan-2-ylsulfinylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CC(C)S(=O)C1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 XEVUCQWBQWHHBF-UHFFFAOYSA-N 0.000 description 1
- FAVPKMFQHQYNSB-UHFFFAOYSA-N 3-(5-propan-2-ylsulfonylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CC(C)S(=O)(=O)C1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 FAVPKMFQHQYNSB-UHFFFAOYSA-N 0.000 description 1
- CLLLIYAKXYKLSF-UHFFFAOYSA-N 3-(5-pyridin-3-ylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CN=CC=1C1=CC=CN=C1 CLLLIYAKXYKLSF-UHFFFAOYSA-N 0.000 description 1
- KGXATMGGZZNBMA-UHFFFAOYSA-N 3-(5-pyrimidin-5-ylpyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CN=CC=1C1=CN=CN=C1 KGXATMGGZZNBMA-UHFFFAOYSA-N 0.000 description 1
- WBJRCQRCLKJHOM-UHFFFAOYSA-N 3-(6-bromopyridin-2-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound BrC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 WBJRCQRCLKJHOM-UHFFFAOYSA-N 0.000 description 1
- RWQABNUWBXVZBE-UHFFFAOYSA-N 3-(6-chloropyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=NC(Cl)=CC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 RWQABNUWBXVZBE-UHFFFAOYSA-N 0.000 description 1
- NNDMVWHOMAYHCB-UHFFFAOYSA-N 3-(6-methoxypyridin-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=NC(OC)=CC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 NNDMVWHOMAYHCB-UHFFFAOYSA-N 0.000 description 1
- HMDWMUZBJSLHCU-UHFFFAOYSA-N 3-(furan-3-yl)-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CC#N)C=1C=COC=1 HMDWMUZBJSLHCU-UHFFFAOYSA-N 0.000 description 1
- XFYCGSYZXBNSBF-UHFFFAOYSA-N 3-(furan-3-yl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C=1C=COC=1 XFYCGSYZXBNSBF-UHFFFAOYSA-N 0.000 description 1
- HEBYRLVQRSTDGJ-UHFFFAOYSA-N 3-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)-3-(trifluoromethyl)pyrazol-4-yl]propan-1-ol Chemical compound N1=C(C(F)(F)F)C(CCCO)=CN1C1=CC=NC2=C1C=CN2 HEBYRLVQRSTDGJ-UHFFFAOYSA-N 0.000 description 1
- FIXWDPZMQVQAJZ-UHFFFAOYSA-N 3-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)imidazol-4-yl]benzonitrile Chemical compound N#CC1=CC=CC(C=2N=CN(C=2)C=2C=3C=CNC=3N=CC=2)=C1 FIXWDPZMQVQAJZ-UHFFFAOYSA-N 0.000 description 1
- AHTVBDRDVRDNDX-UHFFFAOYSA-N 3-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-3-yl]aniline Chemical compound NC1=CC=CC(C2=NN(C=C2)C=2C=3C=CNC=3N=CC=2)=C1 AHTVBDRDVRDNDX-UHFFFAOYSA-N 0.000 description 1
- BUJAIPHWEQGIOR-UHFFFAOYSA-N 3-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-3-yl]benzonitrile Chemical compound N#CC1=CC=CC(C2=NN(C=C2)C=2C=3C=CNC=3N=CC=2)=C1 BUJAIPHWEQGIOR-UHFFFAOYSA-N 0.000 description 1
- IEGBHYMEUPWBAM-UHFFFAOYSA-N 3-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]aniline Chemical compound NC1=CC=CC(C2=CN(N=C2)C=2C=3C=CNC=3N=CC=2)=C1 IEGBHYMEUPWBAM-UHFFFAOYSA-N 0.000 description 1
- OBPVDIAQRCCJGL-UHFFFAOYSA-N 3-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]benzonitrile Chemical compound N#CC1=CC=CC(C2=CN(N=C2)C=2C=3C=CNC=3N=CC=2)=C1 OBPVDIAQRCCJGL-UHFFFAOYSA-N 0.000 description 1
- IXVPQHZZCYTNID-UHFFFAOYSA-N 3-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]phenol Chemical compound OC1=CC=CC(C2=CN(N=C2)C=2C=3C=CNC=3N=CC=2)=C1 IXVPQHZZCYTNID-UHFFFAOYSA-N 0.000 description 1
- ZXKVHNWMEUMMCE-UHFFFAOYSA-N 3-[1-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]ethyl]benzonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1=CC=CC(C#N)=C1 ZXKVHNWMEUMMCE-UHFFFAOYSA-N 0.000 description 1
- PUSFXZKLOYUYBG-UHFFFAOYSA-N 3-[1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]cyclopentyl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C1(CCC#N)CCCC1 PUSFXZKLOYUYBG-UHFFFAOYSA-N 0.000 description 1
- ZFAXWTITSSKZDD-UHFFFAOYSA-N 3-[1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]benzonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(C)C1=CC=CC(C#N)=C1 ZFAXWTITSSKZDD-UHFFFAOYSA-N 0.000 description 1
- DPOFWPNZBVRHRG-UHFFFAOYSA-N 3-[2-(cyanomethoxy)phenyl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound N#CCOC1=CC=CC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 DPOFWPNZBVRHRG-UHFFFAOYSA-N 0.000 description 1
- RYVAIFSJRFTOGK-UHFFFAOYSA-N 3-[2-bromo-5-(cyanomethoxy)phenyl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound BrC1=CC=C(OCC#N)C=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 RYVAIFSJRFTOGK-UHFFFAOYSA-N 0.000 description 1
- RQWGVIYKPBHBCN-UHFFFAOYSA-N 3-[2-cyano-1-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]ethyl]benzonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CC#N)C1=CC=CC(C#N)=C1 RQWGVIYKPBHBCN-UHFFFAOYSA-N 0.000 description 1
- APSABSADNDECFJ-UHFFFAOYSA-N 3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 APSABSADNDECFJ-UHFFFAOYSA-N 0.000 description 1
- QCEZQKJRYJUQDQ-UHFFFAOYSA-N 3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]-n-phenylbenzamide Chemical compound C=1C=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1C(=O)NC1=CC=CC=C1 QCEZQKJRYJUQDQ-UHFFFAOYSA-N 0.000 description 1
- ZRQHCCCEXVOUJN-UHFFFAOYSA-N 3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 ZRQHCCCEXVOUJN-UHFFFAOYSA-N 0.000 description 1
- DNEQCGDNZFTTAJ-UHFFFAOYSA-N 3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]cyclopentane-1-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1CCC(C#N)C1 DNEQCGDNZFTTAJ-UHFFFAOYSA-N 0.000 description 1
- RPNXFYKFEMLUBK-UHFFFAOYSA-N 3-[3-(1h-pyrazol-4-yl)phenyl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CC=CC=1C=1C=NNC=1 RPNXFYKFEMLUBK-UHFFFAOYSA-N 0.000 description 1
- HUGXDNHLBSCMHF-UHFFFAOYSA-N 3-[3-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1,2,4-oxadiazol-5-yl]benzonitrile Chemical compound N#CC1=CC=CC(C=2ON=C(N=2)C=2C=3C=CNC=3N=CC=2)=C1 HUGXDNHLBSCMHF-UHFFFAOYSA-N 0.000 description 1
- DGMJTYGUIGTAPV-UHFFFAOYSA-N 3-[3-(benzylamino)-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]benzonitrile Chemical compound N#CC1=CC=CC(C=2C(=NN(C=2)C=2C=3C=CNC=3N=CC=2)NCC=2C=CC=CC=2)=C1 DGMJTYGUIGTAPV-UHFFFAOYSA-N 0.000 description 1
- XGQUSDPRLSCVEZ-UHFFFAOYSA-N 3-[3-(cyanomethoxy)phenyl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound N#CCOC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 XGQUSDPRLSCVEZ-UHFFFAOYSA-N 0.000 description 1
- NXRSOXHKCMTJCK-UHFFFAOYSA-N 3-[3-(hydroxymethyl)cyclopentyl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1C(CO)CCC1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 NXRSOXHKCMTJCK-UHFFFAOYSA-N 0.000 description 1
- GSWJUWXFLAFQGO-UHFFFAOYSA-N 3-[3-(morpholine-4-carbonyl)phenyl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C=1C=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1C(=O)N1CCOCC1 GSWJUWXFLAFQGO-UHFFFAOYSA-N 0.000 description 1
- RBVJHYPTGOIANP-UHFFFAOYSA-N 3-[3-amino-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]benzonitrile Chemical compound NC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CC=CC(C#N)=C1 RBVJHYPTGOIANP-UHFFFAOYSA-N 0.000 description 1
- RRUSXAOXNPONKQ-UHFFFAOYSA-N 3-[3-amino-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propyl propanoate Chemical compound C(CC)(=O)OCCCN1N=C(C(=C1)C1=C2C(=NC=C1)NC=C2)N RRUSXAOXNPONKQ-UHFFFAOYSA-N 0.000 description 1
- MAMUOQRJDCPGDS-UHFFFAOYSA-N 3-[3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]cyclohexan-1-ol Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1CCCC(O)C1 MAMUOQRJDCPGDS-UHFFFAOYSA-N 0.000 description 1
- GWAKLXKGZFPRPH-UHFFFAOYSA-N 3-[3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]prop-2-en-1-ol Chemical compound C1=C(C=CCO)C(C)=NN1C1=CC=NC2=C1C=CN2 GWAKLXKGZFPRPH-UHFFFAOYSA-N 0.000 description 1
- RIRWSNABCHGOTK-UHFFFAOYSA-N 3-[3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]prop-2-enenitrile Chemical compound C1=C(C=CC#N)C(C)=NN1C1=CC=NC2=C1C=CN2 RIRWSNABCHGOTK-UHFFFAOYSA-N 0.000 description 1
- MJPSDLCKUNCYIP-UHFFFAOYSA-N 3-[3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]propanenitrile Chemical compound C1=C(CCC#N)C(C)=NN1C1=CC=NC2=C1C=CN2 MJPSDLCKUNCYIP-UHFFFAOYSA-N 0.000 description 1
- OGPVINHNJYCGAP-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-3-(1,3-thiazol-5-yl)propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CC#N)C1=CN=CS1 OGPVINHNJYCGAP-UHFFFAOYSA-N 0.000 description 1
- GXDVHYZUQLHOFR-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-3-thiophen-3-ylpropanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CC#N)C=1C=CSC=1 GXDVHYZUQLHOFR-UHFFFAOYSA-N 0.000 description 1
- FQGBLDAAPRYGEX-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-4-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=C(C#N)C=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 FQGBLDAAPRYGEX-UHFFFAOYSA-N 0.000 description 1
- OZTFAGZGHQSMIX-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound N#CC1=CC=CC(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 OZTFAGZGHQSMIX-UHFFFAOYSA-N 0.000 description 1
- QWKYVJFMVVVAGD-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]butan-1-ol Chemical compound C1=NN(C(CCO)C)C=C1C1=CC=NC2=C1C=CN2 QWKYVJFMVVVAGD-UHFFFAOYSA-N 0.000 description 1
- AAYOJTYMORBQSB-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]butanenitrile Chemical compound C1=NN(C(CC#N)C)C=C1C1=CC=NC2=C1C=CN2 AAYOJTYMORBQSB-UHFFFAOYSA-N 0.000 description 1
- JKKLRUPIJUAHCR-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]cyclohexan-1-one Chemical compound C1C(=O)CCCC1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 JKKLRUPIJUAHCR-UHFFFAOYSA-N 0.000 description 1
- XZJYVKOKNMMFGB-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]cyclopentan-1-one Chemical compound C1C(=O)CCC1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 XZJYVKOKNMMFGB-UHFFFAOYSA-N 0.000 description 1
- OCXMTVIFVZNTIB-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]hexanenitrile Chemical compound C1=NN(C(CC#N)CCC)C=C1C1=CC=NC2=C1C=CN2 OCXMTVIFVZNTIB-UHFFFAOYSA-N 0.000 description 1
- YNZWMRMSAZYDLZ-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propan-1-ol Chemical compound C1=NN(CCCO)C=C1C1=CC=NC2=C1C=CN2 YNZWMRMSAZYDLZ-UHFFFAOYSA-N 0.000 description 1
- BRQJJINRYVUFIZ-UHFFFAOYSA-N 3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=NN(CCC#N)C=C1C1=CC=NC2=C1C=CN2 BRQJJINRYVUFIZ-UHFFFAOYSA-N 0.000 description 1
- UMADGGRVTOQZBW-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-3-[3-(trifluoromethoxy)phenyl]propanenitrile Chemical compound FC(F)(F)OC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 UMADGGRVTOQZBW-UHFFFAOYSA-N 0.000 description 1
- WXQMRSJIJGUBLC-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-3-[3-(trifluoromethyl)phenyl]propanenitrile Chemical compound FC(F)(F)C1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 WXQMRSJIJGUBLC-UHFFFAOYSA-N 0.000 description 1
- SMGWYTKHPZOMFF-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-3-[5-(1,3-thiazol-2-ylsulfanyl)pyridin-3-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C(C=1)=CN=CC=1SC1=NC=CS1 SMGWYTKHPZOMFF-UHFFFAOYSA-N 0.000 description 1
- YXGWGLDSROQSIY-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-3-[6-(trifluoromethyl)pyridin-3-yl]propanenitrile Chemical compound C1=NC(C(F)(F)F)=CC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 YXGWGLDSROQSIY-UHFFFAOYSA-N 0.000 description 1
- HPFNKZJTZQFOEN-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]-3-thiophen-3-ylpropanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C=1C=CSC=1 HPFNKZJTZQFOEN-UHFFFAOYSA-N 0.000 description 1
- CJUYDDGQLGQFGK-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanenitrile Chemical compound C1=NN(C(CC#N)C)C=C1C1=NC=NC2=C1C=CN2 CJUYDDGQLGQFGK-UHFFFAOYSA-N 0.000 description 1
- WHAFMTFMBWIHRN-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentan-1-ol Chemical compound C1=NN(C(CCO)CC)C=C1C1=NC=NC2=C1C=CN2 WHAFMTFMBWIHRN-UHFFFAOYSA-N 0.000 description 1
- TWJSVKPPIXMIJC-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentane-1,5-diol Chemical compound C1=NN(C(CCO)CCO)C=C1C1=NC=NC2=C1C=CN2 TWJSVKPPIXMIJC-UHFFFAOYSA-N 0.000 description 1
- YJSYZYAKRLQZCG-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentanedinitrile Chemical compound C1=NN(C(CC#N)CC#N)C=C1C1=NC=NC2=C1C=CN2 YJSYZYAKRLQZCG-UHFFFAOYSA-N 0.000 description 1
- FVFZSSOTHXJXPR-UHFFFAOYSA-N 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentanenitrile Chemical compound C1=NN(C(CC#N)CC)C=C1C1=NC=NC2=C1C=CN2 FVFZSSOTHXJXPR-UHFFFAOYSA-N 0.000 description 1
- KJAFOBQBTYIBSM-UHFFFAOYSA-N 3-[4-(cyanomethoxy)phenyl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=CC(OCC#N)=CC=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 KJAFOBQBTYIBSM-UHFFFAOYSA-N 0.000 description 1
- RSTJBADBYDTUPD-UHFFFAOYSA-N 3-[5-(1-methylpyrazol-4-yl)pyridin-3-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=NN(C)C=C1C1=CN=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 RSTJBADBYDTUPD-UHFFFAOYSA-N 0.000 description 1
- RQAZOWKGXJIQLH-UHFFFAOYSA-N 3-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-oxazol-2-yl]hexanenitrile Chemical compound O1C(C(CC#N)CCC)=NC=C1C1=NC=NC2=C1C=CN2 RQAZOWKGXJIQLH-UHFFFAOYSA-N 0.000 description 1
- JVVPKCLSWIWGEY-UHFFFAOYSA-N 3-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]butanenitrile Chemical compound S1C(C(CC#N)C)=NC=C1C1=NC=NC2=C1C=CN2 JVVPKCLSWIWGEY-UHFFFAOYSA-N 0.000 description 1
- KBKSIQJXURQAKX-UHFFFAOYSA-N 3-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]hexanenitrile Chemical compound S1C(C(CC#N)CCC)=NC=C1C1=NC=NC2=C1C=CN2 KBKSIQJXURQAKX-UHFFFAOYSA-N 0.000 description 1
- ZESLRWYQXMSSGN-UHFFFAOYSA-N 3-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]pentanedinitrile Chemical compound S1C(C(CC#N)CC#N)=NC=C1C1=NC=NC2=C1C=CN2 ZESLRWYQXMSSGN-UHFFFAOYSA-N 0.000 description 1
- VYVHOEXPBGOCDZ-UHFFFAOYSA-N 3-[5-(benzenesulfinyl)pyridin-3-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C=1N=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1S(=O)C1=CC=CC=C1 VYVHOEXPBGOCDZ-UHFFFAOYSA-N 0.000 description 1
- IBZKCYJQNLWBIM-UHFFFAOYSA-N 3-[5-(benzenesulfonyl)pyridin-3-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C=1N=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1S(=O)(=O)C1=CC=CC=C1 IBZKCYJQNLWBIM-UHFFFAOYSA-N 0.000 description 1
- PFAQEHJFJGTYGW-UHFFFAOYSA-N 3-[5-bromo-2-(cyanomethoxy)phenyl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound BrC1=CC=C(OCC#N)C(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 PFAQEHJFJGTYGW-UHFFFAOYSA-N 0.000 description 1
- CAGSCFQUKPDLOU-UHFFFAOYSA-N 3-[6-(dimethylamino)pyridin-2-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound CN(C)C1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=N1 CAGSCFQUKPDLOU-UHFFFAOYSA-N 0.000 description 1
- IYNVYKIVRVKCTJ-UHFFFAOYSA-N 3-[[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]methyl]benzonitrile Chemical compound N#CC1=CC=CC(CN2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 IYNVYKIVRVKCTJ-UHFFFAOYSA-N 0.000 description 1
- XVHOHELMKMNGNY-UHFFFAOYSA-N 3-[hydroxy-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]methyl]benzonitrile Chemical compound C1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C(O)C1=CC=CC(C#N)=C1 XVHOHELMKMNGNY-UHFFFAOYSA-N 0.000 description 1
- ANSAHKCBZZIOPP-UHFFFAOYSA-N 3-[methyl-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]amino]propanenitrile Chemical compound S1C(N(CCC#N)C)=NC=C1C1=NC=NC2=C1C=CN2 ANSAHKCBZZIOPP-UHFFFAOYSA-N 0.000 description 1
- DDAKGHLNTCKIFL-UHFFFAOYSA-N 3-bromo-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound BrC1=CC(C#N)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 DDAKGHLNTCKIFL-UHFFFAOYSA-N 0.000 description 1
- NZJRQYKNACJTEU-UHFFFAOYSA-N 3-chloro-2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound ClC1=CC=CC(C#N)=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 NZJRQYKNACJTEU-UHFFFAOYSA-N 0.000 description 1
- BWEQVAMKNQHFJS-UHFFFAOYSA-N 3-chloro-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound ClC1=CC(C#N)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 BWEQVAMKNQHFJS-UHFFFAOYSA-N 0.000 description 1
- PXBJXXMRMDCVMF-UHFFFAOYSA-N 3-cyclohexyl-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CC#N)C1CCCCC1 PXBJXXMRMDCVMF-UHFFFAOYSA-N 0.000 description 1
- MNCJHFDDDSITIO-UHFFFAOYSA-N 3-cyclohexyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1CCCCC1 MNCJHFDDDSITIO-UHFFFAOYSA-N 0.000 description 1
- OXUJAONXYLDHIK-UHFFFAOYSA-N 3-cyclopentyl-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CC#N)C1CCCC1 OXUJAONXYLDHIK-UHFFFAOYSA-N 0.000 description 1
- YNMYXFHSGSMPFF-UHFFFAOYSA-N 3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]prop-2-enenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(=CC#N)C1CCCC1 YNMYXFHSGSMPFF-UHFFFAOYSA-N 0.000 description 1
- GNDHYESWOWBGMC-UHFFFAOYSA-N 3-cyclopentyl-3-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-oxazol-2-yl]propanenitrile Chemical compound N=1C=C(C=2C=3C=CNC=3N=CN=2)OC=1C(CC#N)C1CCCC1 GNDHYESWOWBGMC-UHFFFAOYSA-N 0.000 description 1
- GBNDDCZODZLNCB-UHFFFAOYSA-N 3-cyclopentyl-3-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]propanenitrile Chemical compound N=1C=C(C=2C=3C=CNC=3N=CN=2)SC=1C(CC#N)C1CCCC1 GBNDDCZODZLNCB-UHFFFAOYSA-N 0.000 description 1
- BHJVROYIOJEFKS-UHFFFAOYSA-N 3-cyclopentylidene-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)=C1CCCC1 BHJVROYIOJEFKS-UHFFFAOYSA-N 0.000 description 1
- MKZZWHGNUHUYCM-UHFFFAOYSA-N 3-cyclopropyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1CC1 MKZZWHGNUHUYCM-UHFFFAOYSA-N 0.000 description 1
- WAZUZDUNUOGIRZ-UHFFFAOYSA-N 3-ethyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentanenitrile Chemical compound C1=NN(C(CC)(CC#N)CC)C=C1C1=NC=NC2=C1C=CN2 WAZUZDUNUOGIRZ-UHFFFAOYSA-N 0.000 description 1
- LZPZFBYRPMORMS-UHFFFAOYSA-N 3-fluoro-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound FC1=CC(C#N)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 LZPZFBYRPMORMS-UHFFFAOYSA-N 0.000 description 1
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 1
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 1
- QTPBAYFSRQFREB-UHFFFAOYSA-N 3-methyl-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]butan-1-ol Chemical compound C1=NN(C(C)(CCO)C)C=C1C1=CC=NC2=C1C=CN2 QTPBAYFSRQFREB-UHFFFAOYSA-N 0.000 description 1
- SWIZYJBOGVTTLD-UHFFFAOYSA-N 3-methyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanenitrile Chemical compound C1=NN(C(C)(CC#N)C)C=C1C1=NC=NC2=C1C=CN2 SWIZYJBOGVTTLD-UHFFFAOYSA-N 0.000 description 1
- YQCNERDTJVEHBB-UHFFFAOYSA-N 3-methyl-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzaldehyde Chemical compound CC1=CC(C=O)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 YQCNERDTJVEHBB-UHFFFAOYSA-N 0.000 description 1
- RXPMDAQIPZWBRY-UHFFFAOYSA-N 3-methyl-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound CC1=CC(C#N)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 RXPMDAQIPZWBRY-UHFFFAOYSA-N 0.000 description 1
- AKUNHDMTESOUJE-UHFFFAOYSA-N 3-methyl-5-[2-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propyl]-1,2,4-oxadiazole Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(C)CC1=NC(C)=NO1 AKUNHDMTESOUJE-UHFFFAOYSA-N 0.000 description 1
- FSWCHUZTZVAVHQ-UHFFFAOYSA-N 3-pyridin-2-yl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CC=CC=N1 FSWCHUZTZVAVHQ-UHFFFAOYSA-N 0.000 description 1
- UYFXFMAEIPPFAG-UHFFFAOYSA-N 3-pyridin-3-yl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CC=CN=C1 UYFXFMAEIPPFAG-UHFFFAOYSA-N 0.000 description 1
- USXGGDFDRFZFHP-UHFFFAOYSA-N 3-pyridin-3-yl-3-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]propanenitrile Chemical compound N=1C=C(C=2C=3C=CNC=3N=CN=2)SC=1C(CC#N)C1=CC=CN=C1 USXGGDFDRFZFHP-UHFFFAOYSA-N 0.000 description 1
- IPRAABXWTRGWDG-UHFFFAOYSA-N 3-pyridin-4-yl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CC=NC=C1 IPRAABXWTRGWDG-UHFFFAOYSA-N 0.000 description 1
- WJOVXYZBOIIIIM-UHFFFAOYSA-N 3-pyrimidin-5-yl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CN=CN=C1 WJOVXYZBOIIIIM-UHFFFAOYSA-N 0.000 description 1
- HBEDAPUPCFVERD-UHFFFAOYSA-N 3-tert-butyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazole-4-carbonitrile Chemical compound C1=C(C#N)C(C(C)(C)C)=NN1C1=CC=NC2=C1C=CN2 HBEDAPUPCFVERD-UHFFFAOYSA-N 0.000 description 1
- NQPAVMOVWRISCT-UHFFFAOYSA-N 4,4,4-trifluoro-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanenitrile Chemical compound C1=NN(C(CC#N)C(F)(F)F)C=C1C1=NC=NC2=C1C=CN2 NQPAVMOVWRISCT-UHFFFAOYSA-N 0.000 description 1
- VOFBAUGXJBKTQG-UHFFFAOYSA-N 4-(1-benzothiophen-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC=C2SC(C3=C4C=CNC4=NC=C3)=CC2=C1 VOFBAUGXJBKTQG-UHFFFAOYSA-N 0.000 description 1
- IGOCJDKGMYDZSD-UHFFFAOYSA-N 4-(1-benzylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC1=CC=CC=C1 IGOCJDKGMYDZSD-UHFFFAOYSA-N 0.000 description 1
- DKPBIDIPOBZZCV-UHFFFAOYSA-N 4-(1-butan-2-ylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C(C)CC)C=C1C1=CC=NC2=C1C=CN2 DKPBIDIPOBZZCV-UHFFFAOYSA-N 0.000 description 1
- RWJKKNBOVOMPSI-UHFFFAOYSA-N 4-(1-cyclohex-2-en-1-ylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CCC=CC1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 RWJKKNBOVOMPSI-UHFFFAOYSA-N 0.000 description 1
- AVEMYBWNWUNQFS-UHFFFAOYSA-N 4-(1-cyclohexylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CCCCC1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 AVEMYBWNWUNQFS-UHFFFAOYSA-N 0.000 description 1
- WHXCFEPIDFOJOG-UHFFFAOYSA-N 4-(1-heptan-2-ylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C(C)CCCCC)C=C1C1=CC=NC2=C1C=CN2 WHXCFEPIDFOJOG-UHFFFAOYSA-N 0.000 description 1
- ALFZLWXPGLHVDX-UHFFFAOYSA-N 4-(1-heptan-4-ylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C(CCC)CCC)C=C1C1=CC=NC2=C1C=CN2 ALFZLWXPGLHVDX-UHFFFAOYSA-N 0.000 description 1
- FJWFBJCRWGBUPF-UHFFFAOYSA-N 4-(1-hex-5-en-3-ylpyrazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NN(C(CC=C)CC)C=C1C1=NC=NC2=C1C=CN2 FJWFBJCRWGBUPF-UHFFFAOYSA-N 0.000 description 1
- UKFXSSUZAILTSC-UHFFFAOYSA-N 4-(1-hex-5-yn-3-ylpyrazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=NN(C(CC#C)CC)C=C1C1=NC=NC2=C1C=CN2 UKFXSSUZAILTSC-UHFFFAOYSA-N 0.000 description 1
- UQWIBBIYUZURMF-UHFFFAOYSA-N 4-(1-pent-3-enylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(CCC=CC)C=C1C1=CC=NC2=C1C=CN2 UQWIBBIYUZURMF-UHFFFAOYSA-N 0.000 description 1
- HVTWKTOPGGHJNU-UHFFFAOYSA-N 4-(1-pentan-2-ylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C(C)CCC)C=C1C1=CC=NC2=C1C=CN2 HVTWKTOPGGHJNU-UHFFFAOYSA-N 0.000 description 1
- LTRQNVGOPBFQPJ-UHFFFAOYSA-N 4-(1-pentan-2-ylpyrazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NN(C(C)CCC)C=C1C1=NC=NC2=C1C=CN2 LTRQNVGOPBFQPJ-UHFFFAOYSA-N 0.000 description 1
- JSMHOWRZRQVQSQ-UHFFFAOYSA-N 4-(1-pentan-3-ylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C(CC)CC)C=C1C1=CC=NC2=C1C=CN2 JSMHOWRZRQVQSQ-UHFFFAOYSA-N 0.000 description 1
- QOUXMGUQHNIMDL-UHFFFAOYSA-N 4-(1-phenylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1C(=C1)C=NN1C1=CC=CC=C1 QOUXMGUQHNIMDL-UHFFFAOYSA-N 0.000 description 1
- NAPJGVICQLGXLG-UHFFFAOYSA-N 4-(2-benzyl-1h-imidazol-5-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound N=1C=C(C=2C=3C=CNC=3N=CC=2)NC=1CC1=CC=CC=C1 NAPJGVICQLGXLG-UHFFFAOYSA-N 0.000 description 1
- UDUPUSRSTJVXCF-UHFFFAOYSA-N 4-(2-phenyl-1h-imidazol-5-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1C(N1)=CN=C1C1=CC=CC=C1 UDUPUSRSTJVXCF-UHFFFAOYSA-N 0.000 description 1
- MGOURJQERILPOM-UHFFFAOYSA-N 4-(2-tert-butyl-1-methylimidazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound N1=C(C(C)(C)C)N(C)C=C1C1=CC=NC2=C1C=CN2 MGOURJQERILPOM-UHFFFAOYSA-N 0.000 description 1
- OPJJTSUYJQWWKH-UHFFFAOYSA-N 4-(3-cyanophenyl)-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazole-3-carbonitrile Chemical compound N#CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CC=CC(C#N)=C1 OPJJTSUYJQWWKH-UHFFFAOYSA-N 0.000 description 1
- XSSQZDSXKHJMLB-UHFFFAOYSA-N 4-(3-methyl-4-phenylpyrazol-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CC=CC=C1 XSSQZDSXKHJMLB-UHFFFAOYSA-N 0.000 description 1
- QWPMRHBEEDAXFS-UHFFFAOYSA-N 4-(3-methyl-4-pyrimidin-5-ylpyrazol-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CN=CN=C1 QWPMRHBEEDAXFS-UHFFFAOYSA-N 0.000 description 1
- LOYAYKYSLRZLNW-UHFFFAOYSA-N 4-(3-methyl-4-thiophen-3-ylpyrazol-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C=1C=CSC=1 LOYAYKYSLRZLNW-UHFFFAOYSA-N 0.000 description 1
- LQLIHELGXSYQFI-UHFFFAOYSA-N 4-(3-phenylpyrazol-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1N(N=1)C=CC=1C1=CC=CC=C1 LQLIHELGXSYQFI-UHFFFAOYSA-N 0.000 description 1
- OXNOAPGVNPMWOT-UHFFFAOYSA-N 4-(4,5,6,7-tetrahydroindazol-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C2CCCCC2=NN1C1=CC=NC2=C1C=CN2 OXNOAPGVNPMWOT-UHFFFAOYSA-N 0.000 description 1
- XWABBWTYQMBTRA-UHFFFAOYSA-N 4-(4-bromo-3-methylpyrazol-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(Br)C(C)=NN1C1=CC=NC2=C1C=CN2 XWABBWTYQMBTRA-UHFFFAOYSA-N 0.000 description 1
- PRCIENPHZZFXTP-UHFFFAOYSA-N 4-(4-bromoimidazol-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NC(Br)=CN1C1=CC=NC2=C1C=CN2 PRCIENPHZZFXTP-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- ULRYCHHDEZQOSD-UHFFFAOYSA-N 4-(4-phenylimidazol-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1N(C=1)C=NC=1C1=CC=CC=C1 ULRYCHHDEZQOSD-UHFFFAOYSA-N 0.000 description 1
- WVFJUBFNJGAHEB-UHFFFAOYSA-N 4-(4-phenylpyrazol-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1N(N=C1)C=C1C1=CC=CC=C1 WVFJUBFNJGAHEB-UHFFFAOYSA-N 0.000 description 1
- LIBGWWIHNJPSSR-UHFFFAOYSA-N 4-(4-pyridin-3-ylpyrazol-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1N(N=C1)C=C1C1=CC=CN=C1 LIBGWWIHNJPSSR-UHFFFAOYSA-N 0.000 description 1
- VGGIEMCXDUMGEL-UHFFFAOYSA-N 4-(4-pyrimidin-4-ylpyrazol-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1N(N=C1)C=C1C1=CC=NC=N1 VGGIEMCXDUMGEL-UHFFFAOYSA-N 0.000 description 1
- YCUHGSDNAUJQGQ-UHFFFAOYSA-N 4-(5-phenylthiophen-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1C(S1)=CC=C1C1=CC=CC=C1 YCUHGSDNAUJQGQ-UHFFFAOYSA-N 0.000 description 1
- UVWPYXOOEMDENN-UHFFFAOYSA-N 4-(cyanomethoxy)-2-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]benzonitrile Chemical compound N#CCOC1=CC=C(C#N)C(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 UVWPYXOOEMDENN-UHFFFAOYSA-N 0.000 description 1
- XPKQBAHJYSCQJF-UHFFFAOYSA-N 4-(cyanomethoxy)-3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]benzonitrile Chemical compound N#CCOC1=CC=C(C#N)C=C1C(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XPKQBAHJYSCQJF-UHFFFAOYSA-N 0.000 description 1
- SISSFPZQFDPIFT-UHFFFAOYSA-N 4-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C12=CC=CC=C2CCCC1N(N=C1)C=C1C1=CC=NC2=C1C=CN2 SISSFPZQFDPIFT-UHFFFAOYSA-N 0.000 description 1
- OPSJJAHKIDSFFB-UHFFFAOYSA-N 4-[1-(1-cyclobutylethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1CCC1 OPSJJAHKIDSFFB-UHFFFAOYSA-N 0.000 description 1
- XHDIGOMAQUEQBO-UHFFFAOYSA-N 4-[1-(1-cyclohexylethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1CCCCC1 XHDIGOMAQUEQBO-UHFFFAOYSA-N 0.000 description 1
- MSXWLBALCWWYNX-UHFFFAOYSA-N 4-[1-(1-cyclopentylethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1CCCC1 MSXWLBALCWWYNX-UHFFFAOYSA-N 0.000 description 1
- YBXXHVGMAXOQJK-UHFFFAOYSA-N 4-[1-(1-cyclopentylpropyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CC)C1CCCC1 YBXXHVGMAXOQJK-UHFFFAOYSA-N 0.000 description 1
- BLLAEKRDPJDWAJ-UHFFFAOYSA-N 4-[1-(1-cyclopentylpropyl)pyrazol-4-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC)C1CCCC1 BLLAEKRDPJDWAJ-UHFFFAOYSA-N 0.000 description 1
- KPTZIFDWCMSAAN-UHFFFAOYSA-N 4-[1-(1-imidazol-1-ylpropan-2-yl)pyrazol-4-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(C)CN1C=CN=C1 KPTZIFDWCMSAAN-UHFFFAOYSA-N 0.000 description 1
- TUOOQFWVPNHXSQ-UHFFFAOYSA-N 4-[1-(1-phenylbutyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CCC)C1=CC=CC=C1 TUOOQFWVPNHXSQ-UHFFFAOYSA-N 0.000 description 1
- XXFCTCGGKZDPCK-UHFFFAOYSA-N 4-[1-(1-phenylethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1=CC=CC=C1 XXFCTCGGKZDPCK-UHFFFAOYSA-N 0.000 description 1
- RUHRCYUKTRUIOG-UHFFFAOYSA-N 4-[1-(1-phenylpropan-2-yl)pyrazol-4-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(C)CC1=CC=CC=C1 RUHRCYUKTRUIOG-UHFFFAOYSA-N 0.000 description 1
- RJFWZTCSGRHOKR-UHFFFAOYSA-N 4-[1-(1-phenylpropyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CC)C1=CC=CC=C1 RJFWZTCSGRHOKR-UHFFFAOYSA-N 0.000 description 1
- NUIRKABRGZSRAQ-UHFFFAOYSA-N 4-[1-(1-thiophen-3-ylpropan-2-yl)pyrazol-4-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(C)CC=1C=CSC=1 NUIRKABRGZSRAQ-UHFFFAOYSA-N 0.000 description 1
- VLIHSNCOIUZBSR-UHFFFAOYSA-N 4-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-3-yl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=NN(C=2C=3C=CNC=3N=CC=2)C=C1 VLIHSNCOIUZBSR-UHFFFAOYSA-N 0.000 description 1
- FWXIBXMIVOPTGJ-UHFFFAOYSA-N 4-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]aniline Chemical compound C1=CC(N)=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1 FWXIBXMIVOPTGJ-UHFFFAOYSA-N 0.000 description 1
- MGOSMMAONVFDFA-UHFFFAOYSA-N 4-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1 MGOSMMAONVFDFA-UHFFFAOYSA-N 0.000 description 1
- SKKGYRXNNUNHHD-UHFFFAOYSA-N 4-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1 SKKGYRXNNUNHHD-UHFFFAOYSA-N 0.000 description 1
- QWCJFEMSUKWZSE-UHFFFAOYSA-N 4-[1-(2,3-dihydro-1h-inden-1-yl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CC2=CC=CC=C2C1N(N=C1)C=C1C1=CC=NC2=C1C=CN2 QWCJFEMSUKWZSE-UHFFFAOYSA-N 0.000 description 1
- PCKUVKTWZIOGRU-UHFFFAOYSA-N 4-[1-(2,5-dimethylphenyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=CC=C(C)C(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 PCKUVKTWZIOGRU-UHFFFAOYSA-N 0.000 description 1
- ZNLPONYTZLZNAR-UHFFFAOYSA-N 4-[1-(2,6-dichlorophenyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC=CC(Cl)=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 ZNLPONYTZLZNAR-UHFFFAOYSA-N 0.000 description 1
- XRRASNMDADUWRT-UHFFFAOYSA-N 4-[1-(2,6-dimethylphenyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=CC=CC(C)=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 XRRASNMDADUWRT-UHFFFAOYSA-N 0.000 description 1
- NDWMZOXGMJDCFE-UHFFFAOYSA-N 4-[1-(2-chlorophenyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 NDWMZOXGMJDCFE-UHFFFAOYSA-N 0.000 description 1
- JRYUBBQUAYYARA-UHFFFAOYSA-N 4-[1-(2-methoxyphenyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=CC=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 JRYUBBQUAYYARA-UHFFFAOYSA-N 0.000 description 1
- KNNMPVOODNBOPR-UHFFFAOYSA-N 4-[1-(2-methyl-4-nitrophenyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=CC([N+]([O-])=O)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 KNNMPVOODNBOPR-UHFFFAOYSA-N 0.000 description 1
- DPVWRLFOQPFFIQ-UHFFFAOYSA-N 4-[1-(2-methylpentan-3-yl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C(C(C)C)CC)C=C1C1=CC=NC2=C1C=CN2 DPVWRLFOQPFFIQ-UHFFFAOYSA-N 0.000 description 1
- YVIBKPAPEOCFGP-UHFFFAOYSA-N 4-[1-(2-methylphenyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=CC=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 YVIBKPAPEOCFGP-UHFFFAOYSA-N 0.000 description 1
- QCCYTIQORCLZMT-UHFFFAOYSA-N 4-[1-(2-methylsulfonylethyl)pyrazol-4-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NN(CCS(=O)(=O)C)C=C1C1=NC=NC2=C1C=CN2 QCCYTIQORCLZMT-UHFFFAOYSA-N 0.000 description 1
- AUSYSAVTHOHINA-UHFFFAOYSA-N 4-[1-(3,5-dimethylphenyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=CC(C)=CC(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 AUSYSAVTHOHINA-UHFFFAOYSA-N 0.000 description 1
- WHJRSHMXXSNWBP-UHFFFAOYSA-N 4-[1-(4-bromo-3,5,6-trifluoropyridin-2-yl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=C(F)C(F)=NC(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1F WHJRSHMXXSNWBP-UHFFFAOYSA-N 0.000 description 1
- SMGOMFJCXSIUNI-UHFFFAOYSA-N 4-[1-(4-imidazol-1-ylbutan-2-yl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)CCN1C=CN=C1 SMGOMFJCXSIUNI-UHFFFAOYSA-N 0.000 description 1
- KAKPCECZICEOKE-UHFFFAOYSA-N 4-[1-(4-methoxybutan-2-yl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C(C)CCOC)C=C1C1=CC=NC2=C1C=CN2 KAKPCECZICEOKE-UHFFFAOYSA-N 0.000 description 1
- JBYYIAPFFJVTHM-UHFFFAOYSA-N 4-[1-(4-phenylbut-3-enyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CCC=CC1=CC=CC=C1 JBYYIAPFFJVTHM-UHFFFAOYSA-N 0.000 description 1
- CYGZDVWGPDUEPZ-UHFFFAOYSA-N 4-[1-(4-phenylbutan-2-yl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)CCC1=CC=CC=C1 CYGZDVWGPDUEPZ-UHFFFAOYSA-N 0.000 description 1
- NPBMGHYDURUBAZ-UHFFFAOYSA-N 4-[1-(4-pyrazol-1-ylbutan-2-yl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)CCN1C=CC=N1 NPBMGHYDURUBAZ-UHFFFAOYSA-N 0.000 description 1
- CECYRNLDDAQSPU-UHFFFAOYSA-N 4-[1-(6,6-dibromohex-5-en-3-yl)pyrazol-4-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NN(C(CC=C(Br)Br)CC)C=C1C1=NC=NC2=C1C=CN2 CECYRNLDDAQSPU-UHFFFAOYSA-N 0.000 description 1
- UCBDAVYDYCPYGI-UHFFFAOYSA-N 4-[1-(cyclohexylmethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC1CCCCC1 UCBDAVYDYCPYGI-UHFFFAOYSA-N 0.000 description 1
- IUMPZECXORUGLN-UHFFFAOYSA-N 4-[1-(cyclopropylmethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC1CC1 IUMPZECXORUGLN-UHFFFAOYSA-N 0.000 description 1
- HYLUMDMBMDXZGW-UHFFFAOYSA-N 4-[1-(furan-2-ylmethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC1=CC=CO1 HYLUMDMBMDXZGW-UHFFFAOYSA-N 0.000 description 1
- ZLVIVDMETWXEMH-UHFFFAOYSA-N 4-[1-(furan-3-ylmethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC=1C=COC=1 ZLVIVDMETWXEMH-UHFFFAOYSA-N 0.000 description 1
- UJVCRJUQYRPVBQ-UHFFFAOYSA-N 4-[1-(naphthalen-2-ylmethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C=C2C=CC=CC2=CC=1CN(N=C1)C=C1C1=CC=NC2=C1C=CN2 UJVCRJUQYRPVBQ-UHFFFAOYSA-N 0.000 description 1
- YWYZNMFJXKODNM-UHFFFAOYSA-N 4-[1-(oxan-2-ylmethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC1CCCCO1 YWYZNMFJXKODNM-UHFFFAOYSA-N 0.000 description 1
- FWDUYQSOHIPKHM-UHFFFAOYSA-N 4-[1-(oxolan-2-ylmethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC1CCCO1 FWDUYQSOHIPKHM-UHFFFAOYSA-N 0.000 description 1
- YUPGEFVFGQTEEX-UHFFFAOYSA-N 4-[1-(oxolan-3-ylmethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC1CCOC1 YUPGEFVFGQTEEX-UHFFFAOYSA-N 0.000 description 1
- FINCFYNGKVBECW-UHFFFAOYSA-N 4-[1-(pyridin-3-ylmethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1CC1=CC=CN=C1 FINCFYNGKVBECW-UHFFFAOYSA-N 0.000 description 1
- AEXHOUJPVURVGG-UHFFFAOYSA-N 4-[1-[(1-methylsulfonylpiperidin-4-yl)methyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CN(S(=O)(=O)C)CCC1CN1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 AEXHOUJPVURVGG-UHFFFAOYSA-N 0.000 description 1
- ADGOXQSPBJHMAB-UHFFFAOYSA-N 4-[1-[(2,6-dichlorophenyl)methyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC=CC(Cl)=C1CN1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 ADGOXQSPBJHMAB-UHFFFAOYSA-N 0.000 description 1
- BRCUDYIFYGGXOL-UHFFFAOYSA-N 4-[1-[(2-bromophenyl)methyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=CC=CC=C1CN1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 BRCUDYIFYGGXOL-UHFFFAOYSA-N 0.000 description 1
- VFVPXSBJCKFCCC-UHFFFAOYSA-N 4-[1-[(2-nitrophenyl)methyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound [O-][N+](=O)C1=CC=CC=C1CN1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 VFVPXSBJCKFCCC-UHFFFAOYSA-N 0.000 description 1
- BIALYXKEVRSRRM-UHFFFAOYSA-N 4-[1-[(3,5-dimethoxyphenyl)methyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=CC(OC)=CC(CN2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 BIALYXKEVRSRRM-UHFFFAOYSA-N 0.000 description 1
- VEMASNDJNTVFCT-UHFFFAOYSA-N 4-[1-[(3-nitrophenyl)methyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound [O-][N+](=O)C1=CC=CC(CN2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 VEMASNDJNTVFCT-UHFFFAOYSA-N 0.000 description 1
- MGHXICVWGTWYOU-UHFFFAOYSA-N 4-[1-[1-(1,2,4-triazol-1-yl)propan-2-yl]pyrazol-4-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(C)CN1C=NC=N1 MGHXICVWGTWYOU-UHFFFAOYSA-N 0.000 description 1
- YWHFXRJONXQDRD-UHFFFAOYSA-N 4-[1-[1-(2,4-dichloro-5-fluorophenyl)ethyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1=CC(F)=C(Cl)C=C1Cl YWHFXRJONXQDRD-UHFFFAOYSA-N 0.000 description 1
- AZINIKIRVOBDRS-UHFFFAOYSA-N 4-[1-[1-(3-fluoro-4-methoxyphenyl)ethyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(F)C(OC)=CC=C1C(C)N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 AZINIKIRVOBDRS-UHFFFAOYSA-N 0.000 description 1
- IMPSDXDGDRSILN-UHFFFAOYSA-N 4-[1-[1-(4-methylsulfonylphenyl)ethyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1=CC=C(S(C)(=O)=O)C=C1 IMPSDXDGDRSILN-UHFFFAOYSA-N 0.000 description 1
- YNDGQIXYUOBYCP-UHFFFAOYSA-N 4-[1-[1-[2-(trifluoromethyl)phenyl]ethyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1=CC=CC=C1C(F)(F)F YNDGQIXYUOBYCP-UHFFFAOYSA-N 0.000 description 1
- LTETXRJDTSYEOZ-UHFFFAOYSA-N 4-[1-[1-[2-chloro-5-(trifluoromethyl)phenyl]ethyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1=CC(C(F)(F)F)=CC=C1Cl LTETXRJDTSYEOZ-UHFFFAOYSA-N 0.000 description 1
- FBBFJGCTDBJIAC-UHFFFAOYSA-N 4-[1-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FBBFJGCTDBJIAC-UHFFFAOYSA-N 0.000 description 1
- MVUGIUIISFQQFR-UHFFFAOYSA-N 4-[1-[1-[3-(trifluoromethyl)phenyl]ethyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1=CC=CC(C(F)(F)F)=C1 MVUGIUIISFQQFR-UHFFFAOYSA-N 0.000 description 1
- IXJQUTNCJXCUOR-UHFFFAOYSA-N 4-[1-[1-[4-(trifluoromethyl)phenyl]ethyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1=CC=C(C(F)(F)F)C=C1 IXJQUTNCJXCUOR-UHFFFAOYSA-N 0.000 description 1
- CDPFCOWTTAKGKP-UHFFFAOYSA-N 4-[1-[1-phenyl-2-(1,2,4-triazol-1-yl)ethyl]pyrazol-4-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NC=NN1CC(N1N=CC(=C1)C=1C=2C=CNC=2N=CN=1)C1=CC=CC=C1 CDPFCOWTTAKGKP-UHFFFAOYSA-N 0.000 description 1
- IBOWDLKMZMYVNP-UHFFFAOYSA-N 4-[1-[1-phenyl-2-(1,2,4-triazol-4-yl)ethyl]pyrazol-4-yl]-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NN=CN1CC(N1N=CC(=C1)C=1C=2C=CNC=2N=CN=1)C1=CC=CC=C1 IBOWDLKMZMYVNP-UHFFFAOYSA-N 0.000 description 1
- NNAAJLCAIRDSID-UHFFFAOYSA-N 4-[1-[2,6-dichloro-4-(trifluoromethyl)phenyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC(C(F)(F)F)=CC(Cl)=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 NNAAJLCAIRDSID-UHFFFAOYSA-N 0.000 description 1
- ITOSTXSZFJJCJG-UHFFFAOYSA-N 4-[1-[2-(trifluoromethyl)phenyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound FC(F)(F)C1=CC=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 ITOSTXSZFJJCJG-UHFFFAOYSA-N 0.000 description 1
- UPCFPKCSOKBCMR-UHFFFAOYSA-N 4-[1-[2-chloro-4-(trifluoromethyl)phenyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC(C(F)(F)F)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 UPCFPKCSOKBCMR-UHFFFAOYSA-N 0.000 description 1
- YYJQZKWSTLADRL-UHFFFAOYSA-N 4-[1-[2-chloro-6-nitro-4-(trifluoromethyl)phenyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC(Cl)=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 YYJQZKWSTLADRL-UHFFFAOYSA-N 0.000 description 1
- ADCQVHRWDHLMKN-UHFFFAOYSA-N 4-[1-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]ethyl]benzonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(C)C1=CC=C(C#N)C=C1 ADCQVHRWDHLMKN-UHFFFAOYSA-N 0.000 description 1
- MSKZMZQLQNEZFK-UHFFFAOYSA-N 4-[1-[4-nitro-2-(trifluoromethyl)phenyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound FC(F)(F)C1=CC([N+](=O)[O-])=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 MSKZMZQLQNEZFK-UHFFFAOYSA-N 0.000 description 1
- FIKVXGUGMRQNIV-UHFFFAOYSA-N 4-[1-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound FC1=CC=C(C(F)(F)F)C=C1CN1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 FIKVXGUGMRQNIV-UHFFFAOYSA-N 0.000 description 1
- ZHYMXRKXONMONQ-UHFFFAOYSA-N 4-[1-[[3-(trifluoromethoxy)phenyl]methyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound FC(F)(F)OC1=CC=CC(CN2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 ZHYMXRKXONMONQ-UHFFFAOYSA-N 0.000 description 1
- ODWWNKGROJEMAL-UHFFFAOYSA-N 4-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound FC(F)(F)C1=CC=CC(CN2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 ODWWNKGROJEMAL-UHFFFAOYSA-N 0.000 description 1
- VLJICVILKGHQOL-UHFFFAOYSA-N 4-[2-(1-phenylethyl)-1h-imidazol-5-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound N=1C=C(C=2C=3C=CNC=3N=CC=2)NC=1C(C)C1=CC=CC=C1 VLJICVILKGHQOL-UHFFFAOYSA-N 0.000 description 1
- IBUPISPSRGZYSY-UHFFFAOYSA-N 4-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]thiophene-2-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CSC(C#N)=C1 IBUPISPSRGZYSY-UHFFFAOYSA-N 0.000 description 1
- UAIOQYJAOYUOBG-UHFFFAOYSA-N 4-[3-(3-methoxyphenyl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=CC=CC(C2=NN(C=C2)C=2C=3C=CNC=3N=CC=2)=C1 UAIOQYJAOYUOBG-UHFFFAOYSA-N 0.000 description 1
- NKTLYKIEUSQFAC-UHFFFAOYSA-N 4-[3-(3-nitrophenyl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound [O-][N+](=O)C1=CC=CC(C2=NN(C=C2)C=2C=3C=CNC=3N=CC=2)=C1 NKTLYKIEUSQFAC-UHFFFAOYSA-N 0.000 description 1
- QPUIIJPOARUVHX-UHFFFAOYSA-N 4-[3-(4-chlorophenyl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(Cl)=CC=C1C1=NN(C=2C=3C=CNC=3N=CC=2)C=C1 QPUIIJPOARUVHX-UHFFFAOYSA-N 0.000 description 1
- AUQZZDZWFYETRT-UHFFFAOYSA-N 4-[3-(4-fluorophenyl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(F)=CC=C1C1=NN(C=2C=3C=CNC=3N=CC=2)C=C1 AUQZZDZWFYETRT-UHFFFAOYSA-N 0.000 description 1
- JAAUCFVESAWHDT-UHFFFAOYSA-N 4-[3-(4-methoxyphenyl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(OC)=CC=C1C1=NN(C=2C=3C=CNC=3N=CC=2)C=C1 JAAUCFVESAWHDT-UHFFFAOYSA-N 0.000 description 1
- BBKOJIAXFCVQOA-UHFFFAOYSA-N 4-[3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]benzonitrile Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CC=C(C#N)C=C1 BBKOJIAXFCVQOA-UHFFFAOYSA-N 0.000 description 1
- SBHXJWYGXZMZMN-UHFFFAOYSA-N 4-[3-methyl-4-(1-methylindol-5-yl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=C3C=CN(C)C3=CC=2)C(C)=NN1C1=CC=NC2=C1C=CN2 SBHXJWYGXZMZMN-UHFFFAOYSA-N 0.000 description 1
- SVFRXSABMIIITI-UHFFFAOYSA-N 4-[4-(1-phenylethenyl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C(=C)C1=CC=CC=C1 SVFRXSABMIIITI-UHFFFAOYSA-N 0.000 description 1
- VUJDQNCNIGUIGZ-UHFFFAOYSA-N 4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound C1=C(C#N)C(C(F)(F)F)=CC(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 VUJDQNCNIGUIGZ-UHFFFAOYSA-N 0.000 description 1
- CAFLLVDAMSUHFY-UHFFFAOYSA-N 4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzene-1,2-dicarbonitrile Chemical compound C1=C(C#N)C(C#N)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 CAFLLVDAMSUHFY-UHFFFAOYSA-N 0.000 description 1
- JXWWUJDWTJYYCS-UHFFFAOYSA-N 4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 JXWWUJDWTJYYCS-UHFFFAOYSA-N 0.000 description 1
- PKVUJPXZYBPDTD-UHFFFAOYSA-N 4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]butanenitrile Chemical compound C1=NN(CCCC#N)C=C1C1=CC=NC2=C1C=CN2 PKVUJPXZYBPDTD-UHFFFAOYSA-N 0.000 description 1
- VNCKSGNSHZQPAG-UHFFFAOYSA-N 4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]pentanamide Chemical compound C1=NN(C(CCC(N)=O)C)C=C1C1=CC=NC2=C1C=CN2 VNCKSGNSHZQPAG-UHFFFAOYSA-N 0.000 description 1
- QYAMYXWZWDNYJS-UHFFFAOYSA-N 4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]pentanenitrile Chemical compound C1=NN(C(CCC#N)C)C=C1C1=CC=NC2=C1C=CN2 QYAMYXWZWDNYJS-UHFFFAOYSA-N 0.000 description 1
- BTFSKZQGESIULP-UHFFFAOYSA-N 4-[4-(2,6-dimethylphenyl)-3-methylpyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=C(C)C=CC=C1C BTFSKZQGESIULP-UHFFFAOYSA-N 0.000 description 1
- FUFRTBJDTLBWJT-UHFFFAOYSA-N 4-[4-(3,5-difluorophenyl)-3-methylpyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CC(F)=CC(F)=C1 FUFRTBJDTLBWJT-UHFFFAOYSA-N 0.000 description 1
- QVEGLYBRAQFIEP-UHFFFAOYSA-N 4-[4-(3-fluorophenyl)-3-methylpyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CC=CC(F)=C1 QVEGLYBRAQFIEP-UHFFFAOYSA-N 0.000 description 1
- ZLGZUPOMSVYTEC-UHFFFAOYSA-N 4-[4-(3-methoxyphenyl)imidazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=CC=CC(C=2N=CN(C=2)C=2C=3C=CNC=3N=CC=2)=C1 ZLGZUPOMSVYTEC-UHFFFAOYSA-N 0.000 description 1
- AFRQGCBBOJWNHC-UHFFFAOYSA-N 4-[4-(3-nitrophenyl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound [O-][N+](=O)C1=CC=CC(C2=CN(N=C2)C=2C=3C=CNC=3N=CC=2)=C1 AFRQGCBBOJWNHC-UHFFFAOYSA-N 0.000 description 1
- DOTRNCLJJNZSCC-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(OC)=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1 DOTRNCLJJNZSCC-UHFFFAOYSA-N 0.000 description 1
- KVDNRJJRCCROHU-UHFFFAOYSA-N 4-[4-(4-nitrophenyl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1 KVDNRJJRCCROHU-UHFFFAOYSA-N 0.000 description 1
- FWBYXUVIMPHZLK-UHFFFAOYSA-N 4-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentan-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=NN(C(CC(C)=O)C)C=C1C1=NC=NC2=C1C=CN2 FWBYXUVIMPHZLK-UHFFFAOYSA-N 0.000 description 1
- HXMFPKLTAKPSCN-UHFFFAOYSA-N 4-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentanenitrile Chemical compound C1=NN(C(CCC#N)C)C=C1C1=NC=NC2=C1C=CN2 HXMFPKLTAKPSCN-UHFFFAOYSA-N 0.000 description 1
- NIXIKOLTUKFOHQ-UHFFFAOYSA-N 4-[4-(cyclohexen-1-yl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CCCC(C2=CN(N=C2)C=2C=3C=CNC=3N=CC=2)=C1 NIXIKOLTUKFOHQ-UHFFFAOYSA-N 0.000 description 1
- VGTJBNBMVQMCAL-UHFFFAOYSA-N 4-[4-(cyclohexen-1-ylmethyl)pyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C=2C=3C=CNC=3N=CC=2)C=C1CC1=CCCCC1 VGTJBNBMVQMCAL-UHFFFAOYSA-N 0.000 description 1
- GGHXTBCUAZWDBU-UHFFFAOYSA-N 4-[4-[3,5-bis(trifluoromethyl)phenyl]-3-methylpyrazol-1-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GGHXTBCUAZWDBU-UHFFFAOYSA-N 0.000 description 1
- SOWDFXXNQNJQAC-UHFFFAOYSA-N 4-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]heptanenitrile Chemical compound S1C(C(CCC#N)CCC)=NC=C1C1=NC=NC2=C1C=CN2 SOWDFXXNQNJQAC-UHFFFAOYSA-N 0.000 description 1
- XJGSJZDKTYSYQY-UHFFFAOYSA-N 4-[[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 XJGSJZDKTYSYQY-UHFFFAOYSA-N 0.000 description 1
- NCRFMZFMXPJTLM-UHFFFAOYSA-N 4-amino-5,6-difluoro-2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzene-1,3-dicarbonitrile Chemical compound NC1=C(F)C(F)=C(C#N)C(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1C#N NCRFMZFMXPJTLM-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- IENYMYBSFYGATC-UHFFFAOYSA-N 4-bromo-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazole-3-carbonitrile Chemical compound N1=C(C#N)C(Br)=CN1C1=CC=NC2=C1C=CN2 IENYMYBSFYGATC-UHFFFAOYSA-N 0.000 description 1
- CEODRDFAPCUYEV-UHFFFAOYSA-N 4-chloro-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound ClC1=CC=C(C#N)C=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 CEODRDFAPCUYEV-UHFFFAOYSA-N 0.000 description 1
- MKBICQOOEBQMNQ-UHFFFAOYSA-N 4-chloro-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound ClC1=CC=C(C#N)C=C1N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 MKBICQOOEBQMNQ-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- GGXXASVWZWLPJE-UHFFFAOYSA-N 4-cyclopentyl-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]butanamide Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CCC(=O)N)C1CCCC1 GGXXASVWZWLPJE-UHFFFAOYSA-N 0.000 description 1
- BYPCYQPASFKGOL-UHFFFAOYSA-N 4-cyclopentyl-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]butanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CC=2)C=NN1C(CCC#N)C1CCCC1 BYPCYQPASFKGOL-UHFFFAOYSA-N 0.000 description 1
- QQKLULYCCPELLE-UHFFFAOYSA-N 4-cyclopropyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)CC1CC1 QQKLULYCCPELLE-UHFFFAOYSA-N 0.000 description 1
- HLYAWDDOHBFRTD-UHFFFAOYSA-N 4-fluoro-2-[1-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-3-yl]phenol Chemical compound OC1=CC=C(F)C=C1C1=NN(C=2C=3C=CNC=3N=CC=2)C=C1 HLYAWDDOHBFRTD-UHFFFAOYSA-N 0.000 description 1
- GRUWCEQHXOCEHR-UHFFFAOYSA-N 4-fluoro-2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound FC1=CC=C(C#N)C(N2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=C1 GRUWCEQHXOCEHR-UHFFFAOYSA-N 0.000 description 1
- FXPVFIGMSPCKHM-UHFFFAOYSA-N 4-methyl-3-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound CC1=CC=C(C#N)C=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 FXPVFIGMSPCKHM-UHFFFAOYSA-N 0.000 description 1
- FULRJSWMDFPUSX-UHFFFAOYSA-N 4-methyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound CC1=CC=C(C#N)C=C1N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 FULRJSWMDFPUSX-UHFFFAOYSA-N 0.000 description 1
- XXGFORSBJZTDKY-UHFFFAOYSA-N 4-methyl-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]pentan-2-one Chemical compound C1=NN(C(C)(C)CC(=O)C)C=C1C1=CC=NC2=C1C=CN2 XXGFORSBJZTDKY-UHFFFAOYSA-N 0.000 description 1
- GMNSOVZULKWRQH-UHFFFAOYSA-N 4-methyl-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]pentanamide Chemical compound C1=NN(C(C)(CCC(N)=O)C)C=C1C1=CC=NC2=C1C=CN2 GMNSOVZULKWRQH-UHFFFAOYSA-N 0.000 description 1
- QAFMORKSPWOGOW-UHFFFAOYSA-N 4-methyl-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]pentanenitrile Chemical compound C1=NN(C(C)(CCC#N)C)C=C1C1=CC=NC2=C1C=CN2 QAFMORKSPWOGOW-UHFFFAOYSA-N 0.000 description 1
- GKDVNABMPZGSOV-UHFFFAOYSA-N 4-methyl-4-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentanenitrile Chemical compound C1=NN(C(C)(CCC#N)C)C=C1C1=NC=NC2=C1C=CN2 GKDVNABMPZGSOV-UHFFFAOYSA-N 0.000 description 1
- PWBMKZHSOIJGEJ-UHFFFAOYSA-N 5,5,5-trifluoro-4-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentanenitrile Chemical compound C1=NN(C(CCC#N)C(F)(F)F)C=C1C1=NC=NC2=C1C=CN2 PWBMKZHSOIJGEJ-UHFFFAOYSA-N 0.000 description 1
- LMKHFHSFTZKHHA-UHFFFAOYSA-N 5,5-dimethyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]hexanenitrile Chemical compound C1=NN(C(CC#N)CC(C)(C)C)C=C1C1=NC=NC2=C1C=CN2 LMKHFHSFTZKHHA-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- JDVMHHOMCMCZFQ-UHFFFAOYSA-N 5-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]pyridine-3-carbonitrile Chemical compound N#CC1=CN=CC(C2=CN(N=C2)C=2C=3C=CNC=3N=CC=2)=C1 JDVMHHOMCMCZFQ-UHFFFAOYSA-N 0.000 description 1
- NEZCABPBWSTXKS-UHFFFAOYSA-N 5-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]-n-phenylpyridine-3-carboxamide Chemical compound C=1N=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1C(=O)NC1=CC=CC=C1 NEZCABPBWSTXKS-UHFFFAOYSA-N 0.000 description 1
- WVNCJLMCVQTXTO-UHFFFAOYSA-N 5-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]benzene-1,3-dicarbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CC(C#N)=CC(C#N)=C1 WVNCJLMCVQTXTO-UHFFFAOYSA-N 0.000 description 1
- PXRXOLWDVATQFL-UHFFFAOYSA-N 5-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]furan-3-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CC(C#N)=CO1 PXRXOLWDVATQFL-UHFFFAOYSA-N 0.000 description 1
- XVDOPTZMOIWSBQ-UHFFFAOYSA-N 5-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]pyridine-2-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CC=C(C#N)N=C1 XVDOPTZMOIWSBQ-UHFFFAOYSA-N 0.000 description 1
- RHQRWZUIHVWBLX-UHFFFAOYSA-N 5-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]pyridine-3-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CN=CC(C#N)=C1 RHQRWZUIHVWBLX-UHFFFAOYSA-N 0.000 description 1
- MMLCBUMCJUVALW-UHFFFAOYSA-N 5-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]thiophene-2-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CC=C(C#N)S1 MMLCBUMCJUVALW-UHFFFAOYSA-N 0.000 description 1
- MJLKOGXSSAPYHK-UHFFFAOYSA-N 5-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]thiophene-3-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CC(C#N)=CS1 MJLKOGXSSAPYHK-UHFFFAOYSA-N 0.000 description 1
- WUUVSRVRPFPOFQ-UHFFFAOYSA-N 5-[2-cyano-1-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]ethyl]pyridine-3-carbonitrile Chemical compound N=1C=C(C=2C=3C=CNC=3N=CN=2)SC=1C(CC#N)C1=CN=CC(C#N)=C1 WUUVSRVRPFPOFQ-UHFFFAOYSA-N 0.000 description 1
- BPWKTWPNMYUKOD-UHFFFAOYSA-N 5-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound C1=C(C#N)C(C(F)(F)F)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 BPWKTWPNMYUKOD-UHFFFAOYSA-N 0.000 description 1
- UAVBVIGJXCLNFE-UHFFFAOYSA-N 5-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]hexanenitrile Chemical compound C1=NN(C(CCCC#N)C)C=C1C1=CC=NC2=C1C=CN2 UAVBVIGJXCLNFE-UHFFFAOYSA-N 0.000 description 1
- PYTPCLRXVQNJHT-UHFFFAOYSA-N 5-bromo-2-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]benzonitrile Chemical compound N#CC1=CC(Br)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 PYTPCLRXVQNJHT-UHFFFAOYSA-N 0.000 description 1
- QFCXFSVBKPWIKR-UHFFFAOYSA-N 5-methyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]hexanenitrile Chemical compound C1=NN(C(CC#N)CC(C)C)C=C1C1=NC=NC2=C1C=CN2 QFCXFSVBKPWIKR-UHFFFAOYSA-N 0.000 description 1
- IVRFMCDCILFQBX-UHFFFAOYSA-N 5-methyl-3-[5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1,3-thiazol-2-yl]hexanenitrile Chemical compound S1C(C(CC#N)CC(C)C)=NC=C1C1=NC=NC2=C1C=CN2 IVRFMCDCILFQBX-UHFFFAOYSA-N 0.000 description 1
- WDJYVOKJVVMXRK-UHFFFAOYSA-N 5-methyl-3-[[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]methyl]-1,2-oxazole Chemical compound O1C(C)=CC(CN2N=CC(=C2)C=2C=3C=CNC=3N=CC=2)=N1 WDJYVOKJVVMXRK-UHFFFAOYSA-N 0.000 description 1
- ZFAMDSILECCONY-UHFFFAOYSA-N 5-methylsulfanyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentanenitrile Chemical compound C1=NN(C(CC#N)CCSC)C=C1C1=NC=NC2=C1C=CN2 ZFAMDSILECCONY-UHFFFAOYSA-N 0.000 description 1
- CJMDVMHMMHTWIN-UHFFFAOYSA-N 5-methylsulfinyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentanenitrile Chemical compound C1=NN(C(CC#N)CCS(=O)C)C=C1C1=NC=NC2=C1C=CN2 CJMDVMHMMHTWIN-UHFFFAOYSA-N 0.000 description 1
- DMRQIQJJVGGHQX-UHFFFAOYSA-N 5-methylsulfonyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]pentanenitrile Chemical compound C1=NN(C(CC#N)CCS(=O)(=O)C)C=C1C1=NC=NC2=C1C=CN2 DMRQIQJJVGGHQX-UHFFFAOYSA-N 0.000 description 1
- LRUCWELUCGBTEZ-UHFFFAOYSA-N 5-nitro-2-(1h-pyrrolo[2,3-b]pyridin-4-yl)indazole Chemical compound C1=C2C=C([N+](=O)[O-])C=CC2=NN1C1=CC=NC2=C1C=CN2 LRUCWELUCGBTEZ-UHFFFAOYSA-N 0.000 description 1
- BJVZRDANBJZUGI-UHFFFAOYSA-N 6-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]pyridine-2-carbonitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC#N)C1=CC=CC(C#N)=N1 BJVZRDANBJZUGI-UHFFFAOYSA-N 0.000 description 1
- HPAYRKWTERIXEJ-UHFFFAOYSA-N 6-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]hexanenitrile Chemical compound C1=NN(CCCCCC#N)C=C1C1=CC=NC2=C1C=CN2 HPAYRKWTERIXEJ-UHFFFAOYSA-N 0.000 description 1
- DWALUJKFLVAFDD-UHFFFAOYSA-N 6-nitro-2-(1h-pyrrolo[2,3-b]pyridin-4-yl)indazole Chemical compound N1=C2C=C([N+](=O)[O-])C=CC2=CN1C1=CC=NC2=C1C=CN2 DWALUJKFLVAFDD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- LDUXSGACSMUGPR-UHFFFAOYSA-N C(N)(OC(C)(C)C1=CC(=CC=C1)C(CC#N)N1N=CC(=C1)C=1C2=C(N=CN1)NC=C2)=O Chemical compound C(N)(OC(C)(C)C1=CC(=CC=C1)C(CC#N)N1N=CC(=C1)C=1C2=C(N=CN1)NC=C2)=O LDUXSGACSMUGPR-UHFFFAOYSA-N 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000019743 Cranial nerve injury Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100256637 Drosophila melanogaster senju gene Proteins 0.000 description 1
- 241001212789 Dynamis Species 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 208000008017 Hypohidrosis Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- 108010000837 Janus Kinase 1 Proteins 0.000 description 1
- 108010019437 Janus Kinase 2 Proteins 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 208000003423 Mucocele Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- STFCMOQUWGFXCX-UHFFFAOYSA-N N1=CN=C(C2=C1NC=C2)C=2C=NN(C2)C(CCC#N)CCC Chemical compound N1=CN=C(C2=C1NC=C2)C=2C=NN(C2)C(CCC#N)CCC STFCMOQUWGFXCX-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- QDFKDDCKKXSMEJ-UHFFFAOYSA-N OC(=O)C=CC1=CC=CC=C1.OC(=O)C(=C)C1=CC=CC=C1 Chemical compound OC(=O)C=CC1=CC=CC=C1.OC(=O)C(=C)C1=CC=CC=C1 QDFKDDCKKXSMEJ-UHFFFAOYSA-N 0.000 description 1
- 206010072139 Ocular rosacea Diseases 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 244000113945 Pinus torreyana Species 0.000 description 1
- 235000006235 Pinus torreyana Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 102000001744 Purinergic P2Y2 Receptors Human genes 0.000 description 1
- 108010029812 Purinergic P2Y2 Receptors Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 1
- BMYKYIMUZUCZAZ-UHFFFAOYSA-N [3-[3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]phenyl]methanol Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CC=CC(CO)=C1 BMYKYIMUZUCZAZ-UHFFFAOYSA-N 0.000 description 1
- HAIREAPDDZUMCQ-UHFFFAOYSA-N [3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]-piperidin-1-ylmethanone Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C(=O)N1CCCCC1 HAIREAPDDZUMCQ-UHFFFAOYSA-N 0.000 description 1
- ITDZZZNARHWVQA-UHFFFAOYSA-N [3-methyl-4-[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]phenyl]methanol Chemical compound CC1=CC(CO)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 ITDZZZNARHWVQA-UHFFFAOYSA-N 0.000 description 1
- FGDYBRPRGQDCHO-UHFFFAOYSA-N [3-methyl-4-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]phenyl]methanol Chemical compound CC1=CC(CO)=CC=C1N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 FGDYBRPRGQDCHO-UHFFFAOYSA-N 0.000 description 1
- RSDCZOXHJSXDTH-UHFFFAOYSA-N [4-[[4-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]methyl]cyclohexyl]methanol Chemical compound C1CC(CO)CCC1CN1N=CC(C=2C=3C=CNC=3N=CC=2)=C1 RSDCZOXHJSXDTH-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000002187 allostimulatory effect Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- UIERETOOQGIECD-ARJAWSKDSA-N angelic acid Chemical compound C\C=C(\C)C(O)=O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 206010002512 anhidrosis Diseases 0.000 description 1
- 230000037001 anhydrosis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- HXXAWVHKWBCXDB-UHFFFAOYSA-N cyclohexyl-[1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]methanol Chemical compound C1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C(O)C1CCCCC1 HXXAWVHKWBCXDB-UHFFFAOYSA-N 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 108010067071 duramycin Proteins 0.000 description 1
- IWCWQNVIUXZOMJ-MISYRCLQSA-N ecabet Chemical compound OC(=O)[C@@](C)([C@@H]1CC2)CCC[C@]1(C)C1=C2C=C(C(C)C)C(S(O)(=O)=O)=C1 IWCWQNVIUXZOMJ-MISYRCLQSA-N 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- OYDJJOSMXZJFSC-UHFFFAOYSA-N ethyl 1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=CC=NC2=C1C=CN2 OYDJJOSMXZJFSC-UHFFFAOYSA-N 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 206010015915 eye discharge Diseases 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PSTBYXSYWMQNJV-UHFFFAOYSA-N hexa-1,5-diene-2,3-diol Chemical compound OC(=C)C(O)CC=C PSTBYXSYWMQNJV-UHFFFAOYSA-N 0.000 description 1
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical group C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 229940060928 lacrisert Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- SFWLDKQAUHFCBS-WWXQEMPQSA-N lancovutide Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@@H](CCCCNC[C@H]4C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)N[C@H]([C@@H](SC[C@H](NC(=O)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSC3C)CSC2)C(=O)N4)C)C(=O)N1)C(O)=O)[C@@H](O)C(O)=O)=O)C(C)C)C1=CC=CC=C1 SFWLDKQAUHFCBS-WWXQEMPQSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- RVGLGHVJXCETIO-UHFFFAOYSA-N lodoxamide Chemical compound OC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(O)=O)=C1Cl RVGLGHVJXCETIO-UHFFFAOYSA-N 0.000 description 1
- 229960004305 lodoxamide Drugs 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 229960001798 loteprednol Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- BLYOHBPLFYXHQA-UHFFFAOYSA-N n,n-bis(prop-2-enyl)prop-2-enamide Chemical compound C=CCN(CC=C)C(=O)C=C BLYOHBPLFYXHQA-UHFFFAOYSA-N 0.000 description 1
- OVHHHVAVHBHXAK-UHFFFAOYSA-N n,n-diethylprop-2-enamide Chemical compound CCN(CC)C(=O)C=C OVHHHVAVHBHXAK-UHFFFAOYSA-N 0.000 description 1
- ZYOWVXWRTSOWBA-UHFFFAOYSA-N n,n-dimethyl-4-[3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1C ZYOWVXWRTSOWBA-UHFFFAOYSA-N 0.000 description 1
- RPKINLXJEDDUDE-UHFFFAOYSA-N n-(3-cyanophenyl)-3-[[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]methyl]benzamide Chemical compound C=1C=CC(CN2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1C(=O)NC1=CC=CC(C#N)=C1 RPKINLXJEDDUDE-UHFFFAOYSA-N 0.000 description 1
- UJEAYTXQIODDJJ-UHFFFAOYSA-N n-[(3-phenylphenyl)methyl]-2-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanamide Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC)C(=O)NCC(C=1)=CC=CC=1C1=CC=CC=C1 UJEAYTXQIODDJJ-UHFFFAOYSA-N 0.000 description 1
- DVXQVBJUZKRJOD-UHFFFAOYSA-N n-[(4-phenylphenyl)methyl]-2-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanamide Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC)C(=O)NCC(C=C1)=CC=C1C1=CC=CC=C1 DVXQVBJUZKRJOD-UHFFFAOYSA-N 0.000 description 1
- COGQENLQTVAYQZ-UHFFFAOYSA-N n-[3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 COGQENLQTVAYQZ-UHFFFAOYSA-N 0.000 description 1
- MHQBSZUVMOXKJV-UHFFFAOYSA-N n-[3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=C1 MHQBSZUVMOXKJV-UHFFFAOYSA-N 0.000 description 1
- CYWKMSDOEMFKBF-UHFFFAOYSA-N n-[3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]phenyl]pyridine-3-carboxamide Chemical compound C=1C=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1NC(=O)C1=CC=CN=C1 CYWKMSDOEMFKBF-UHFFFAOYSA-N 0.000 description 1
- PPNQGMKAYPUULI-UHFFFAOYSA-N n-[3-[[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]methyl]phenyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NC=2C=C(CN3N=CC(=C3)C=3C=4C=CNC=4N=CN=3)C=CC=2)=C1 PPNQGMKAYPUULI-UHFFFAOYSA-N 0.000 description 1
- VEVYJHGTEFGURU-UHFFFAOYSA-N n-[3-[[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]methyl]phenyl]benzenesulfonamide Chemical compound C=1C=CC(CN2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1NS(=O)(=O)C1=CC=CC=C1 VEVYJHGTEFGURU-UHFFFAOYSA-N 0.000 description 1
- QHURSQMJZCDGBO-UHFFFAOYSA-N n-[4-(3-cyanophenyl)-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-3-yl]acetamide Chemical compound CC(=O)NC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1C1=CC=CC(C#N)=C1 QHURSQMJZCDGBO-UHFFFAOYSA-N 0.000 description 1
- NJWBMTUUYOAHOW-UHFFFAOYSA-N n-[4-[3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CN(C=2C=3C=CNC=3N=CC=2)N=C1C NJWBMTUUYOAHOW-UHFFFAOYSA-N 0.000 description 1
- ODXBOOZFGUXLIM-UHFFFAOYSA-N n-[[3-methyl-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-4-yl]methyl]aniline Chemical compound CC1=NN(C=2C=3C=CNC=3N=CC=2)C=C1CNC1=CC=CC=C1 ODXBOOZFGUXLIM-UHFFFAOYSA-N 0.000 description 1
- HZJXDNVFGKUXHU-UHFFFAOYSA-N n-benzyl-3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]benzamide Chemical compound C=1C=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1C(=O)NCC1=CC=CC=C1 HZJXDNVFGKUXHU-UHFFFAOYSA-N 0.000 description 1
- IDZMFWNJETYMNA-UHFFFAOYSA-N n-benzyl-3-[2-cyano-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]ethyl]benzenesulfonamide Chemical compound C=1C=CC(C(CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)=CC=1S(=O)(=O)NCC1=CC=CC=C1 IDZMFWNJETYMNA-UHFFFAOYSA-N 0.000 description 1
- RXYVIPANZNNMHZ-UHFFFAOYSA-N n-methyl-n-phenyl-4-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1,3-thiazol-2-amine Chemical compound N=1C(C=2C=3C=CNC=3N=CC=2)=CSC=1N(C)C1=CC=CC=C1 RXYVIPANZNNMHZ-UHFFFAOYSA-N 0.000 description 1
- DAGMUZJHAPOKEW-UHFFFAOYSA-N n-methyl-n-propyl-4-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1,3-thiazol-2-amine Chemical compound S1C(N(C)CCC)=NC(C=2C=3C=CNC=3N=CC=2)=C1 DAGMUZJHAPOKEW-UHFFFAOYSA-N 0.000 description 1
- IPZNHIZMYLXIHS-UHFFFAOYSA-N n-phenyl-2-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanamide Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1C(CC)C(=O)NC1=CC=CC=C1 IPZNHIZMYLXIHS-UHFFFAOYSA-N 0.000 description 1
- XNWLOKQUTTVIJS-UHFFFAOYSA-N n-phenyl-4-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1,3-thiazol-2-amine Chemical compound N=1C(C=2C=3C=CNC=3N=CC=2)=CSC=1NC1=CC=CC=C1 XNWLOKQUTTVIJS-UHFFFAOYSA-N 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 206010069732 neurotrophic keratopathy Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- PMOWTIHVNWZYFI-UHFFFAOYSA-N o-Coumaric acid Natural products OC(=O)C=CC1=CC=CC=C1O PMOWTIHVNWZYFI-UHFFFAOYSA-N 0.000 description 1
- NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920000548 poly(silane) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- ZVOCIIHCJJEFRQ-BHXBHYJPSA-N propan-2-yl (5s,8e,10e,12r)-5,12-dihydroxypentadeca-8,10-dien-6,14-diynoate Chemical compound CC(C)OC(=O)CCC[C@H](O)C#C\C=C\C=C\[C@H](O)CC#C ZVOCIIHCJJEFRQ-BHXBHYJPSA-N 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000000486 refractive cornea Anatomy 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229940053174 restasis Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- PMOWTIHVNWZYFI-AATRIKPKSA-N trans-2-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1O PMOWTIHVNWZYFI-AATRIKPKSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
- 229940055059 vexol Drugs 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- BICRTLVBTLFLRD-PTWUADNWSA-N voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 description 1
- 229960005289 voclosporin Drugs 0.000 description 1
- 108010057559 voclosporin Proteins 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10224208P | 2008-10-02 | 2008-10-02 | |
| US61/102,242 | 2008-10-02 | ||
| PCT/US2009/059203 WO2010039939A1 (en) | 2008-10-02 | 2009-10-01 | Janus kinase inhibitors for treatment of dry eye and other eye related diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042933A Division JP2015127332A (ja) | 2008-10-02 | 2015-03-04 | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504639A true JP2012504639A (ja) | 2012-02-23 |
| JP2012504639A5 JP2012504639A5 (enExample) | 2013-02-07 |
Family
ID=41572626
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530218A Withdrawn JP2012504639A (ja) | 2008-10-02 | 2009-10-01 | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 |
| JP2015042933A Pending JP2015127332A (ja) | 2008-10-02 | 2015-03-04 | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 |
| JP2017000685A Pending JP2017057231A (ja) | 2008-10-02 | 2017-01-05 | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 |
| JP2017246134A Pending JP2018044012A (ja) | 2008-10-02 | 2017-12-22 | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 |
| JP2020002245A Pending JP2020050682A (ja) | 2008-10-02 | 2020-01-09 | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015042933A Pending JP2015127332A (ja) | 2008-10-02 | 2015-03-04 | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 |
| JP2017000685A Pending JP2017057231A (ja) | 2008-10-02 | 2017-01-05 | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 |
| JP2017246134A Pending JP2018044012A (ja) | 2008-10-02 | 2017-12-22 | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 |
| JP2020002245A Pending JP2020050682A (ja) | 2008-10-02 | 2020-01-09 | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20100113416A1 (enExample) |
| EP (2) | EP3042655A1 (enExample) |
| JP (5) | JP2012504639A (enExample) |
| AR (2) | AR073530A1 (enExample) |
| CA (2) | CA2738520C (enExample) |
| CL (1) | CL2009001884A1 (enExample) |
| CY (1) | CY1117317T1 (enExample) |
| DK (1) | DK2349260T3 (enExample) |
| ES (1) | ES2564203T3 (enExample) |
| HR (1) | HRP20160330T1 (enExample) |
| HU (1) | HUE028499T2 (enExample) |
| PL (1) | PL2349260T3 (enExample) |
| PT (1) | PT2349260E (enExample) |
| RS (1) | RS54651B1 (enExample) |
| SI (1) | SI2349260T1 (enExample) |
| SM (1) | SMT201600080B (enExample) |
| TW (2) | TWI591068B (enExample) |
| WO (1) | WO2010039939A1 (enExample) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016537390A (ja) * | 2013-11-20 | 2016-12-01 | レスターティアーズ，エルエルシー | ハーダー腺分泌物に見出される化合物で眼疾患を治療する方法 |
| KR20170095310A (ko) * | 2014-12-16 | 2017-08-22 | 켄타우루스 바이오파마 컴퍼니 리미티드 | 피롤로피리미딘 화합물 |
| WO2018056269A1 (ja) * | 2016-09-20 | 2018-03-29 | 参天製薬株式会社 | Ｊａｋ阻害剤を含有する点眼剤 |
| WO2018056268A1 (ja) * | 2016-09-20 | 2018-03-29 | 参天製薬株式会社 | 炎症性眼疾患の治療及び／又は予防剤 |
| JP2018536634A (ja) * | 2015-12-11 | 2018-12-13 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | アゼチジン誘導体、その調製方法、及びその使用 |
| JP2019521980A (ja) * | 2016-06-16 | 2019-08-08 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶 |
| JP2019529397A (ja) * | 2016-09-07 | 2019-10-17 | グリア エルエルシーGlia, Llc | 脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療 |
| JP2020506906A (ja) * | 2017-01-23 | 2020-03-05 | シャンハイ ロングウッド バイオファーマシューティカルズ カンパニー リミテッドＳｈａｎｇｈａｉ Ｌｏｎｇｗｏｏｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | Ｊａｋ酵素阻害剤及びその製造方法と用途 |
| JP2020522462A (ja) * | 2017-06-07 | 2020-07-30 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | アゼチジン誘導体の固体形態並びにその調製方法及びその使用 |
| WO2023100918A1 (ja) * | 2021-11-30 | 2023-06-08 | 興和株式会社 | 新規ニコチンアミド化合物及びその用途 |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060106020A1 (en) * | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| PT2049123E (pt) | 2006-08-03 | 2013-03-06 | Horizon Pharma Ag | Tratamento de doença reumatóide com glucocorticóide de libertação retardada |
| KR20090082507A (ko) | 2006-11-20 | 2009-07-30 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 통증 및 소양증 치료용 방법, 조성물 및 키트 |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| EA020777B1 (ru) * | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
| WO2010083283A2 (en) | 2009-01-15 | 2010-07-22 | Incyte Corporation | Processes for preparing jak inhibitors and related intermediate compounds |
| EP2391369A1 (en) * | 2009-01-26 | 2011-12-07 | Nitec Pharma AG | Delayed-release glucocorticoid treatment of asthma |
| BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| NZ596479A (en) * | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2011006073A1 (en) | 2009-07-10 | 2011-01-13 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| TW201113285A (en) * | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EA021478B1 (ru) * | 2009-10-09 | 2015-06-30 | Инсайт Корпорейшн | ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА |
| EA022120B1 (ru) | 2009-10-20 | 2015-11-30 | Целльзом Лимитид | Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak |
| CA2792508C (en) * | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| WO2011134831A1 (en) | 2010-04-30 | 2011-11-03 | Cellzome Limited | Pyrazole compounds as jak inhibitors |
| EA202091303A3 (ru) | 2010-05-21 | 2021-05-31 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
| US20130071415A1 (en) * | 2010-05-28 | 2013-03-21 | Biocryst Pharmaceuticals, Inc. | Heterocyclic Compounds as Janus Kinase Inhibitors |
| US20130143915A1 (en) | 2010-07-01 | 2013-06-06 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| JP2013534233A (ja) | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | 選択的ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体 |
| AU2011328237A1 (en) | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EA036970B1 (ru) * | 2010-11-19 | 2021-01-21 | Инсайт Холдингс Корпорейшн | Применение {1-{1-[3-фтор-2-(трифтометил)изоникотиноил] пиперидин-4-ил}-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)-1н-пиразол-1-ил]азетидин-3-ил}ацетонитрила для лечения заболеваний, связанных с активностью jak1 |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| WO2012112847A1 (en) | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
| AU2012232658B2 (en) | 2011-03-22 | 2016-06-09 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| ES2548414T3 (es) | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
| WO2013014162A1 (en) | 2011-07-28 | 2013-01-31 | Cellzome Limited | Heterocyclyl pyrimidine analogues as jak inhibitors |
| WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| WO2013023119A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | JAK P13K/mTOR COMBINATION THERAPY |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| KR20140063700A (ko) | 2011-09-20 | 2014-05-27 | 셀좀 리미티드 | 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체 |
| SG11201400988SA (en) * | 2011-10-21 | 2014-07-30 | Glaxosmithkline Llc | Compounds and methods for enhancing innate immune responses |
| EP2794598A1 (en) | 2011-12-23 | 2014-10-29 | Cellzome Limited | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
| WO2013108644A1 (ja) * | 2012-01-20 | 2013-07-25 | 京都府公立大学法人 | レバミピドのアレルギー性結膜炎治療剤 |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| US9296725B2 (en) | 2012-05-24 | 2016-03-29 | Cellzome Limited | Heterocyclyl pyrimidine analogues as TYK2 inhibitors |
| WO2014045305A1 (en) | 2012-09-21 | 2014-03-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| CA2888816A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| KR102242077B1 (ko) | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| WO2014118388A1 (en) | 2013-02-04 | 2014-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| CR20190156A (es) | 2013-05-17 | 2019-05-16 | Incyte Corp | Derivados de bipirazol como inhibidores jak |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| CA3158254C (en) | 2014-04-08 | 2024-05-21 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitors |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| CN105924444B (zh) * | 2015-03-11 | 2019-06-18 | 苏州晶云药物科技股份有限公司 | Jak抑制剂的晶型及其制备方法 |
| US11021443B2 (en) | 2015-08-03 | 2021-06-01 | President And Fellows Of Harvard College | Charged ion channel blockers and methods for use |
| CN106554363B (zh) * | 2015-09-28 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 一种Baricitinib中间体的制备方法 |
| TWI710560B (zh) | 2015-11-03 | 2020-11-21 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療呼吸疾病之jak激酶抑制劑化合物 |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| ES2882118T3 (es) | 2015-12-31 | 2021-12-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Procedimiento de síntesis de ruxolitinib |
| CN107573348B (zh) * | 2016-01-29 | 2019-09-03 | 上海宣创生物科技有限公司 | 巴瑞克替尼三氟乙酸盐b晶型及其制备方法 |
| CN105601635B (zh) * | 2016-02-01 | 2017-12-12 | 上海宣创生物科技有限公司 | 巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法 |
| CN107200742A (zh) * | 2016-03-18 | 2017-09-26 | 罗欣生物科技（上海）有限公司 | 一种巴瑞克替尼磷酸盐晶体及其制备方法 |
| AU2017315343A1 (en) | 2016-08-24 | 2019-02-28 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
| CZ2016816A3 (cs) | 2016-12-21 | 2018-07-04 | Zentiva, K.S. | Krystalické formy 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrilu s kyselinou fosforečnou a způsob jejich přípravy |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| US10759865B2 (en) * | 2017-08-22 | 2020-09-01 | Eyal Levit | Treatment of diabetes mellitus |
| US20220143075A1 (en) * | 2017-09-25 | 2022-05-12 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| BR112020008850A2 (pt) | 2017-11-03 | 2020-10-20 | Aclaris Therapeutics, Inc. | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 |
| US10800775B2 (en) * | 2017-11-03 | 2020-10-13 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same |
| CN109867676B (zh) * | 2017-12-01 | 2020-10-30 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
| CN109867675B (zh) * | 2017-12-01 | 2021-01-19 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| MD3746429T2 (ro) | 2018-01-30 | 2022-08-31 | Incyte Corp | Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă) |
| CA3091339A1 (en) | 2018-02-16 | 2019-08-22 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
| WO2019191679A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| KR20260080448A (ko) | 2018-03-30 | 2026-06-02 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
| CN112567247A (zh) | 2018-04-13 | 2021-03-26 | 因赛特公司 | 用于移植物抗宿主病的生物标志物 |
| IT201800005599A1 (it) | 2018-05-22 | 2019-11-22 | Lente a contatto morbida | |
| IL278889B2 (en) | 2018-06-01 | 2025-11-01 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| JP7591500B2 (ja) | 2018-08-10 | 2024-11-28 | アクラリス セラピューティクス，インコーポレイテッド | ピロロピリミジンｉｔｋ阻害剤 |
| AU2019365255B2 (en) | 2018-10-26 | 2025-06-12 | Viramal Limited | Mucoadhesive gel composition |
| KR20210109522A (ko) | 2018-10-31 | 2021-09-06 | 인사이트 코포레이션 | 혈액 질환의 치료를 위한 병용 요법 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| EP3659583B1 (en) | 2018-11-30 | 2023-06-07 | Viramal Limited | A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| WO2020173364A1 (zh) * | 2019-02-27 | 2020-09-03 | 四川科伦博泰生物医药股份有限公司 | 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途 |
| CN113811305A (zh) | 2019-03-11 | 2021-12-17 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| US10828287B2 (en) | 2019-03-11 | 2020-11-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CA3129089A1 (en) | 2019-03-11 | 2020-09-17 | Bridget Mccarthy Cole | Ester substituted ion channel blockers and methods for use |
| US11377422B2 (en) | 2019-03-11 | 2022-07-05 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| PH12021552036A1 (en) | 2019-05-02 | 2022-05-23 | Aclaris Therapeutics Inc | Substituted pyrrolopyridines as jak inhibitors |
| CN110028509B (zh) * | 2019-05-27 | 2020-10-09 | 上海勋和医药科技有限公司 | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2021072116A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| CA3155568A1 (en) | 2019-11-06 | 2021-05-14 | Bridget Mccarthy Cole | Charged ion channel blockers and methods for use |
| AU2020380118B2 (en) | 2019-11-06 | 2026-06-11 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| TW202131926A (zh) | 2019-11-22 | 2021-09-01 | 美商英塞特公司 | 包含alk2抑制劑及jak2抑制劑的組合療法 |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US11332446B2 (en) | 2020-03-11 | 2022-05-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| SI4157831T1 (sl) | 2020-06-02 | 2025-02-28 | Incyte Corporation | Postopki za pripravo zaviralca jak1 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| TWI908843B (zh) * | 2020-07-30 | 2025-12-21 | 日商樂敦製藥股份有限公司 | 水性組成物 |
| IL300555A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK inhibitor |
| CA3192055A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
| CN114085224A (zh) * | 2020-08-25 | 2022-02-25 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶化合物的制备方法 |
| IL303238A (en) | 2020-12-08 | 2023-07-01 | Incyte Corp | Jak1 pathway inhibitors for the treatment of vitiligo |
| CN118420621A (zh) * | 2021-02-07 | 2024-08-02 | 南京知和医药科技有限公司 | 一种磺酰胺类多环化合物及其制备方法与用途 |
| CN114957260B (zh) * | 2021-02-26 | 2024-04-09 | 南京知和医药科技有限公司 | 一种巴瑞替尼衍生物及其制备方法与用途 |
| AU2022270072A1 (en) | 2021-05-03 | 2023-11-02 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| CA3226714A1 (en) | 2021-07-12 | 2023-01-19 | Incyte Corporation | Process and intermediates for preparing baricitinib |
| WO2023172240A1 (en) * | 2022-03-07 | 2023-09-14 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
| KR20240069235A (ko) | 2022-11-11 | 2024-05-20 | 주식회사 다운컴퍼니 | 디지털 에이전시 기반의 그로스 해킹 테스팅 플랫폼 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006502183A (ja) * | 2002-09-20 | 2006-01-19 | アルコン，インコーポレイテッド | ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用 |
| WO2007070514A1 (en) * | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2985589A (en) * | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
| DE3220113A1 (de) * | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
| US4402832A (en) * | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US4498991A (en) * | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
| IT1258781B (it) * | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5630943A (en) * | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
| US6060038A (en) * | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| US5908841A (en) * | 1997-08-11 | 1999-06-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido 3,2-b:2',3'-e!azepine-6-ones and their use in the prevention of treatment of HIV infection |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
| US6375839B1 (en) * | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
| FR2785196B1 (fr) * | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
| US6413419B1 (en) * | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| HUP0203895A3 (en) * | 1999-12-24 | 2004-09-28 | Aventis Pharma Ltd West Mallin | Substituted azaindoles and pharmaceutical compositions containing them and their use |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| PT1142566E (pt) * | 2000-04-07 | 2004-02-27 | Medidom Lab | Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80 |
| US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| US6335342B1 (en) * | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| CA2413313C (en) * | 2000-06-23 | 2011-06-14 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
| JP2004520347A (ja) * | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 |
| JP4316893B2 (ja) * | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｓｒｃおよび他のプロテインキナーゼのインヒビター |
| CA2455181C (en) * | 2001-08-01 | 2010-04-06 | Merck & Co., Inc. | Benzimidazo[4,5-f]isoquinolinone derivatives |
| CN100391958C (zh) | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
| PT1441737E (pt) | 2001-10-30 | 2006-12-29 | Dana Farber Cancer Inst Inc | Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3 |
| US6949668B2 (en) * | 2001-11-30 | 2005-09-27 | Teijin Limited | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| BR0309844A (pt) * | 2002-05-07 | 2005-02-15 | Control Delivery Sys Inc | Processos para formação de um dispositivo para a distribuição de droga |
| CA2486183C (en) * | 2002-05-23 | 2012-01-10 | Cytopia Pty Ltd. | Protein kinase inhibitors |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| WO2004007472A1 (ja) * | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
| US20040204404A1 (en) * | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| TWI335819B (en) * | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| CA2515132C (en) * | 2003-02-07 | 2012-01-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrroles useful as inhibitors of protein kinases |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7183941B2 (en) * | 2003-07-30 | 2007-02-27 | Lear Corporation | Bus-based appliance remote control |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| US7358255B2 (en) * | 2003-10-24 | 2008-04-15 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for keratoconjunctival disorder |
| US7338968B2 (en) * | 2003-12-19 | 2008-03-04 | Schering Corporation | Thiadiazoles AS CXC- and CC- chemokine receptor ligands |
| US20050153989A1 (en) * | 2004-01-13 | 2005-07-14 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| US20060106020A1 (en) * | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| WO2006001463A1 (ja) * | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| DE102004038530B3 (de) * | 2004-08-07 | 2006-01-05 | Universität Mannheim | Verfahren und Vorrichtung zur Herstellung einer optischen Verbindung zwischen einem optoelektronischen Bauelement und einem Lichtwellenleiter |
| CN101899049A (zh) * | 2004-10-13 | 2010-12-01 | 霍夫曼-拉罗奇有限公司 | 二取代吡唑并苯并二氮杂*类 |
| US7517870B2 (en) * | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
| WO2006065916A1 (en) * | 2004-12-14 | 2006-06-22 | Alcon, Inc. | Method of treating dry eye disorders using 13(s)-hode and its analogs |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| US8633205B2 (en) * | 2005-02-03 | 2014-01-21 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases |
| JP2008545660A (ja) * | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| WO2006133426A2 (en) * | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| CN102127078A (zh) * | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| WO2007038215A1 (en) * | 2005-09-22 | 2007-04-05 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| WO2007053452A1 (en) * | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007062459A1 (en) * | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| WO2007076348A2 (en) * | 2005-12-23 | 2007-07-05 | Smithkline Beecham Corporation | Azaindole inhibitors of aurora kinases |
| WO2007084667A2 (en) * | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| EP1981887A2 (en) * | 2006-02-01 | 2008-10-22 | SmithKline Beecham Corporation | Pyrrolo[2,3,b]pyridine derivatives useful as raf kinase inhibitors |
| RU2008140144A (ru) * | 2006-03-10 | 2010-04-20 | Оно Фармасьютикал Ко., Лтд. (Jp) | Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента |
| EP2003132B1 (en) * | 2006-04-03 | 2014-03-05 | Astellas Pharma Inc. | Oxadiazole derivatives as S1P1 agonists |
| JP2009532475A (ja) * | 2006-04-05 | 2009-09-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | ヤヌスキナーゼの阻害剤として有用なデアザプリン |
| US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| BRPI0713187A2 (pt) * | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
| US8492378B2 (en) * | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| CA2660560A1 (en) * | 2006-08-16 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Pyrazine compounds, their use and methods of preparation |
| TW200837064A (en) * | 2006-10-04 | 2008-09-16 | Pharmacopeia Inc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
| US7750007B2 (en) * | 2006-11-06 | 2010-07-06 | Supergen, Inc. | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| WO2008104835A2 (en) * | 2006-12-05 | 2008-09-04 | Myriad Group Ag | System and method of providing access to instant messaging services via a wireless network |
| RU2009127095A (ru) * | 2006-12-15 | 2011-01-20 | Эбботт Лэборетриз (Us) | Новые оксадиазольные соединения |
| MX2009006543A (es) * | 2006-12-20 | 2009-06-26 | Amgen Inc | Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer. |
| ES2415863T3 (es) * | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
| CL2008001709A1 (es) * | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| WO2009007839A1 (en) * | 2007-07-11 | 2009-01-15 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
| BRPI0815042A2 (pt) * | 2007-08-01 | 2015-02-10 | Pfizer | Compostos de pirazol |
| WO2009049028A1 (en) * | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| WO2009089804A1 (en) * | 2008-01-18 | 2009-07-23 | Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. | Novel cytostatic 7-deazapurine nucleosides |
| MY165582A (en) * | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| WO2010083283A2 (en) * | 2009-01-15 | 2010-07-22 | Incyte Corporation | Processes for preparing jak inhibitors and related intermediate compounds |
| US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
| BRPI1012108B8 (pt) * | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| NZ596479A (en) * | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) * | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EA021478B1 (ru) * | 2009-10-09 | 2015-06-30 | Инсайт Корпорейшн | ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА |
| US20110207754A1 (en) * | 2010-02-18 | 2011-08-25 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
| CA2792508C (en) * | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
-
2009
- 2009-09-23 CL CL2009001884A patent/CL2009001884A1/es unknown
- 2009-10-01 RS RS20160064A patent/RS54651B1/sr unknown
- 2009-10-01 CA CA2738520A patent/CA2738520C/en active Active
- 2009-10-01 TW TW098133430A patent/TWI591068B/zh active
- 2009-10-01 EP EP15195683.6A patent/EP3042655A1/en not_active Withdrawn
- 2009-10-01 DK DK09737257.7T patent/DK2349260T3/en active
- 2009-10-01 HU HUE09737257A patent/HUE028499T2/en unknown
- 2009-10-01 SI SI200931388A patent/SI2349260T1/sl unknown
- 2009-10-01 CA CA3064247A patent/CA3064247A1/en not_active Abandoned
- 2009-10-01 HR HRP20160330TT patent/HRP20160330T1/hr unknown
- 2009-10-01 PT PT97372577T patent/PT2349260E/pt unknown
- 2009-10-01 WO PCT/US2009/059203 patent/WO2010039939A1/en not_active Ceased
- 2009-10-01 PL PL09737257T patent/PL2349260T3/pl unknown
- 2009-10-01 EP EP09737257.7A patent/EP2349260B1/en active Active
- 2009-10-01 TW TW106111786A patent/TWI643622B/zh active
- 2009-10-01 ES ES09737257.7T patent/ES2564203T3/es active Active
- 2009-10-01 US US12/571,834 patent/US20100113416A1/en not_active Abandoned
- 2009-10-01 JP JP2011530218A patent/JP2012504639A/ja not_active Withdrawn
- 2009-10-02 AR ARP090103822A patent/AR073530A1/es not_active Application Discontinuation
-
2012
- 2012-08-01 US US13/564,271 patent/US20120301464A1/en not_active Abandoned
-
2015
- 2015-03-04 JP JP2015042933A patent/JP2015127332A/ja active Pending
-
2016
- 2016-03-22 SM SM201600080T patent/SMT201600080B/it unknown
- 2016-03-22 CY CY20161100241T patent/CY1117317T1/el unknown
- 2016-05-16 US US15/156,125 patent/US20170087158A1/en not_active Abandoned
-
2017
- 2017-01-05 JP JP2017000685A patent/JP2017057231A/ja active Pending
- 2017-12-22 JP JP2017246134A patent/JP2018044012A/ja active Pending
-
2018
- 2018-09-19 AR ARP180102672A patent/AR112822A2/es unknown
-
2019
- 2019-11-18 US US16/686,934 patent/US20200093825A1/en not_active Abandoned
-
2020
- 2020-01-09 JP JP2020002245A patent/JP2020050682A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006502183A (ja) * | 2002-09-20 | 2006-01-19 | アルコン，インコーポレイテッド | ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用 |
| WO2007070514A1 (en) * | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016537390A (ja) * | 2013-11-20 | 2016-12-01 | レスターティアーズ，エルエルシー | ハーダー腺分泌物に見出される化合物で眼疾患を治療する方法 |
| JP2018052965A (ja) * | 2013-11-20 | 2018-04-05 | レスターティアーズ，エルエルシー | ハーダー腺分泌物に見出される化合物で眼疾患を治療する方法 |
| KR20170095310A (ko) * | 2014-12-16 | 2017-08-22 | 켄타우루스 바이오파마 컴퍼니 리미티드 | 피롤로피리미딘 화합물 |
| JP2017537950A (ja) * | 2014-12-16 | 2017-12-21 | ケンタウルス バイオファーマ カンパニー リミテッド | ピロロピリミジン化合物 |
| KR102634308B1 (ko) | 2014-12-16 | 2024-02-06 | 켄타우루스 바이오파마 컴퍼니 리미티드 | 피롤로피리미딘 화합물 |
| US10561657B2 (en) | 2014-12-16 | 2020-02-18 | Centaurus Biophrama Co., Ltd. | Pyrrolopyrimidine compound |
| JP2018536634A (ja) * | 2015-12-11 | 2018-12-13 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | アゼチジン誘導体、その調製方法、及びその使用 |
| JP2019521980A (ja) * | 2016-06-16 | 2019-08-08 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶 |
| JP2019529397A (ja) * | 2016-09-07 | 2019-10-17 | グリア エルエルシーGlia, Llc | 脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療 |
| JP7378781B2 (ja) | 2016-09-07 | 2023-11-14 | グリア エルエルシー | 脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療 |
| JP2018048134A (ja) * | 2016-09-20 | 2018-03-29 | 参天製薬株式会社 | Ｊａｋ阻害剤を含有する点眼剤 |
| JP2018048133A (ja) * | 2016-09-20 | 2018-03-29 | 参天製薬株式会社 | 炎症性眼疾患の治療及び／又は予防剤 |
| WO2018056268A1 (ja) * | 2016-09-20 | 2018-03-29 | 参天製薬株式会社 | 炎症性眼疾患の治療及び／又は予防剤 |
| WO2018056269A1 (ja) * | 2016-09-20 | 2018-03-29 | 参天製薬株式会社 | Ｊａｋ阻害剤を含有する点眼剤 |
| JP2020506906A (ja) * | 2017-01-23 | 2020-03-05 | シャンハイ ロングウッド バイオファーマシューティカルズ カンパニー リミテッドＳｈａｎｇｈａｉ Ｌｏｎｇｗｏｏｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | Ｊａｋ酵素阻害剤及びその製造方法と用途 |
| JP7112755B2 (ja) | 2017-01-23 | 2022-08-04 | シャンハイ ロングウッド バイオファーマシューティカルズ カンパニー リミテッド | Ｊａｋ酵素阻害剤及びその製造方法と用途 |
| JP2020522462A (ja) * | 2017-06-07 | 2020-07-30 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | アゼチジン誘導体の固体形態並びにその調製方法及びその使用 |
| JP7120505B2 (ja) | 2017-06-07 | 2022-08-17 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | アゼチジン誘導体の固体形態並びにその調製方法及びその使用 |
| WO2023100918A1 (ja) * | 2021-11-30 | 2023-06-08 | 興和株式会社 | 新規ニコチンアミド化合物及びその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20160330T1 (hr) | 2016-05-06 |
| TWI643622B (zh) | 2018-12-11 |
| PL2349260T3 (pl) | 2016-07-29 |
| PT2349260E (pt) | 2016-03-07 |
| ES2564203T3 (es) | 2016-03-18 |
| TW201801731A (zh) | 2018-01-16 |
| HK1160607A1 (zh) | 2012-08-10 |
| AR073530A1 (es) | 2010-11-10 |
| SMT201600080B (it) | 2016-07-01 |
| HUE028499T2 (en) | 2016-12-28 |
| CA3064247A1 (en) | 2010-04-08 |
| US20170087158A1 (en) | 2017-03-30 |
| CA2738520A1 (en) | 2010-04-08 |
| TW201018689A (en) | 2010-05-16 |
| CY1117317T1 (el) | 2017-04-26 |
| CL2009001884A1 (es) | 2010-05-14 |
| DK2349260T3 (en) | 2016-01-25 |
| EP3042655A1 (en) | 2016-07-13 |
| RS54651B1 (sr) | 2016-08-31 |
| EP2349260B1 (en) | 2016-01-06 |
| SI2349260T1 (sl) | 2016-05-31 |
| AR112822A2 (es) | 2019-12-18 |
| JP2015127332A (ja) | 2015-07-09 |
| TWI591068B (zh) | 2017-07-11 |
| JP2018044012A (ja) | 2018-03-22 |
| US20100113416A1 (en) | 2010-05-06 |
| CA2738520C (en) | 2020-03-10 |
| EP2349260A1 (en) | 2011-08-03 |
| US20120301464A1 (en) | 2012-11-29 |
| JP2017057231A (ja) | 2017-03-23 |
| US20200093825A1 (en) | 2020-03-26 |
| JP2020050682A (ja) | 2020-04-02 |
| WO2010039939A1 (en) | 2010-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020050682A (ja) | ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤 | |
| US20220282254A1 (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd | |
| ES2602577T3 (es) | Derivados de azetidina y ciclobutano como inhibidores de JAK | |
| EA050167B1 (ru) | Комбинированная терапия, включающая ингибитор пути jak и ингибитор rock |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140314 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140324 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140617 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150304 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150326 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150417 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20151113 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20160810 |